使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Welcome to Baxter International's fourth quarter earnings conference call. Your lines will remain in a listen-only mode until the question-and-answer segment of today's call.
歡迎參加百特國際(Baxter International)第四季財報電話會議。在今天電話會議的問答環節開始之前,您的線路將維持僅收聽模式。
(Operator Instructions)
(接線員指示)
As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time. I would now like to turn the call over to Ms Mary Kay Ladone, Corporate Vice President - Investor Relations at Baxter International. Ms Ladone, you may begin.
提醒各位,本次電話會議由百特錄音並受著作權保護。未經百特許可,不得錄製或轉播。如您有任何異議,請於此時中斷連線。現在我想將電話會議交給百特國際企業副總裁—投資人關係部的 Mary Kay Ladone 女士。Ladone 女士,您可以開始了。
- Corporate VP - IR
- Corporate VP - IR
Good morning. Welcome to our fourth quarter 2012 earnings conference call. Joining me today are -- Bob Parkinson, CEO and Chairman of Baxter International; Bob Hombach, Chief Financial Officer; and Ludwig Hantson, President of Baxter BioScience. Before we get started, let me remind you that this presentation, including comments regarding our financial outlook, new product developments and regulatory matters contain forward-looking statements that involve risks and uncertainties. Of course, our actual results could differ materially from our current expectations. Please refer to today's press release and our SEC filings for more details concerning factors that could cause actual results to differ materially. In addition, in today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance. A reconciliation of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in our earnings release issued this morning and available on our website. Now, I'd like to turn the call over to Bob Parkinson.
各位早安。歡迎參加我們 2012 年第四季財報電話會議。今天與我一同出席的有——百特國際執行長兼董事長 Bob Parkinson、財務長 Bob Hombach,以及百特生物科學(Baxter BioScience)總裁 Ludwig Hantson。在開始之前,提醒各位,本簡報(包括關於我們財務展望、新產品開發及法規事項的評論)包含前瞻性陳述,涉及風險與不確定性。當然,我們的實際結果可能與目前預期有重大差異。有關可能導致實際結果與預期有重大差異之因素的更多資訊,請參閱今日新聞稿及我們向美國證券交易委員會(SEC)提交的文件。此外,在今天的電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續性業務表現。今日所討論之非 GAAP 財務衡量指標與可比較之 GAAP 財務衡量指標的調節表,已包含於今早發布並可於我們網站取得的財報新聞稿中。現在,我想把電話會議交給 Bob Parkinson。
- Chairman & CEO
- Chairman & CEO
Thanks, Mary Kay. Good morning. Thank you for calling in. We're pleased today to announce financial results for the fourth quarter and full year 2012 and also provide you with our financial guidance for 2013. As you saw in the press release that was issued earlier this morning, adjusted EPS in the fourth quarter increased 8% to $1.26 per diluted share. For the full year adjusted EPS increased 5% to $4.53 per diluted share. On a reported basis, worldwide sales in the fourth quarter increased 4%. For the full year sales increased 2%. After adjusting for foreign currency, Baxter's global sales increased 5% for both the quarter and full year 2012. Importantly, we continue to generate significant cash flow, which exceeded $3.1 billion for the year, a record level, while maintaining a disciplined capital allocation strategy of returning value to shareholders through both dividend increases and share repurchases.
謝謝你,Mary Kay。各位早安。感謝各位來電參與。我們很高興今天公布 2012 年第四季與全年財務結果,並同時提供 2013 年的財務指引。如各位今早稍早發布的新聞稿所見,第四季調整後每股盈餘(adjusted EPS)成長 8%,至稀釋後每股 1.26 美元。全年調整後每股盈餘成長 5%,至稀釋後每股 4.53 美元。以申報口徑(reported basis)計算,第四季全球銷售額成長 4%。全年銷售額成長 2%。在剔除外匯影響後,百特全球銷售額在本季與 2012 全年皆成長 5%。更重要的是,我們持續創造可觀的現金流,全年超過 31 億美元,創下歷史新高;同時維持嚴謹的資本配置策略,透過提高股利與庫藏股回購兩種方式回饋股東價值。
Even in the face of a challenging macroeconomic environment, Baxter expanded access and increased standards of care around the world, invested to enhance its competitive position, innovated and advanced the new product pipeline and delivered solid financial results, while providing an attractive return for shareholders. In 2013 and beyond, we'll focus on the four growth vectors that support our objectives and enable us to serve the interest of patients, providers and other key stakeholders. As we've previously discussed, these four vectors include -- enhancing growth by optimizing our core business portfolio; advancing the Company's new product pipeline; capitalizing on the opportunity to develop new business models, which include public and private partnerships; and pursuing business development initiatives that deliver enhanced returns in the near and long-term. With this in mind, Baxter will fulfill our mission of improving quality and access to care as we save and sustain lives globally.
即使面對具挑戰性的總體經濟環境,百特仍在全球擴大可近性並提升照護標準,投資以強化競爭地位,創新並推進新產品研發管線,交出穩健的財務成果,同時為股東提供具吸引力的報酬。在 2013 年及未來,我們將聚焦於四個成長向量,以支持我們的目標,並使我們能服務病患、醫療提供者及其他關鍵利害關係人的利益。如我們先前所討論,這四個向量包括——透過最佳化核心業務組合以提升成長;推進公司的新產品研發管線;把握發展新商業模式的機會(包括公私部門合作夥伴關係);以及推動能在短期與長期帶來更佳報酬的業務發展計畫。秉持此一方向,百特將履行我們的使命:在全球提升照護品質與可近性,拯救並延續生命。
Many achievements throughout 2012 reflect these priorities and were highlighted in this morning's press release, so I won't take too much time to review them in depth. But let me take just a moment to underscore just a few key accomplishments. First, within the base business, we continue to derive significant benefits by taking full advantage of the existing opportunities to bring our products and therapies to various markets more effectively. This includes geographic expansion, particularly in emerging markets where 2012 sales totaled approximately $3 billion in growth is approaching double digits. For example, we penetrated new markets with our Inhaled Anesthetics portfolio, introduced OLIMEL and NUMETA triple-chamber nutritional therapies in more than a dozen new countries and received approval for ADVATE in China, where more than 50,000 people are living with Hemophilia A. We're also very pleased with the continued success of ADVATE and the momentum that we're gaining from the new prophylaxis label in the United States, as evidenced by the acceleration in sales growth to double digits this year. We remain committed to meeting patient needs by augmenting our plasma manufacturing footprint with both internal capacity expansions and external collaborations, such as the agreement with Sanguin, which was announced earlier this year.
2012 年的許多成果反映了這些優先事項,且已在今早的新聞稿中重點說明,因此我不會花太多時間深入回顧。不過,讓我用一點時間強調幾項關鍵成就。首先,在基礎業務方面,我們持續透過充分把握既有機會,以更有效的方式將產品與療法導入各市場,獲得顯著效益。這包括地域擴張,特別是在新興市場;2012 年新興市場銷售額合計約 30 億美元,成長率接近兩位數。例如,我們以吸入式麻醉藥(Inhaled Anesthetics)產品組合打入新市場,在十多個新國家推出 OLIMEL 與 NUMETA 三腔室營養療法,並在中國取得 ADVATE 的核准;中國有超過 50,000 名 A 型血友病患者。我們也對 ADVATE 的持續成功以及在美國因新增預防性用藥標示(prophylaxis label)所帶來的動能感到非常振奮,從今年銷售成長加速至兩位數即可見一斑。我們仍致力於滿足病患需求,透過內部產能擴增與外部合作(例如今年稍早宣布與 Sanguin 的協議)來擴大我們的血漿製造布局。
Second, throughout 2012, we meaningfully advanced our new product pipeline. We received approval of new indications for life saving therapies including GAMMAGARD LIQUID for the treatment of multifocal motor neuropathy and TISSEEL, for general hemostasis in surgery. We further advanced clinical programs into late stage development with the initiation of several Phase III trials, including the stem cell trial for myocardial ischemia, a trial for BAX 855, a full-length longer acting recombinant Factor VIII therapy and a second confirmatory Phase III trial evaluating GAMMAGARD LIQUID as a potential treatment for Alzheimer's Disease. We also completed a number of clinical trials in 2012. For instance, we recently concluded the clinical phase of our first Phase III Alzheimer's trial and expect to announce results in the second quarter of 2013. We completed the pivotal trial of BAX 326, a recombinant Factor IX protein and filed for US regulatory approval in the third quarter of 2012. Recently, patients completed treatment in the first trial in the United States evaluating the performance and safety of our new home hemodialysis system, which will support European CE marketing in 2013.
第二,在 2012 年期間,我們大幅推進了新產品研發管線。我們取得多項救命療法的新適應症核准,包括 GAMMAGARD LIQUID 用於治療多灶性運動神經病變,以及 TISSEEL 用於手術的一般止血。我們也透過啟動多項第三期(Phase III)試驗,將臨床計畫進一步推進至後期開發,包括:用於心肌缺血的幹細胞試驗、BAX 855(一種全長、作用時間更長的重組第八凝血因子 Factor VIII 療法)試驗,以及第二項確認性第三期試驗,用以評估 GAMMAGARD LIQUID 作為阿茲海默症潛在治療的效果。我們也在 2012 年完成了多項臨床試驗。例如,我們近期完成首項第三期阿茲海默症試驗的臨床階段,並預期於 2013 年第二季公布結果。我們完成 BAX 326(重組第九凝血因子 Factor IX 蛋白)的關鍵性試驗,並於 2012 年第三季向美國提出法規核准申請。近期,病患已完成美國首項評估我們新型居家血液透析系統效能與安全性的試驗治療,該結果將支持我們於 2013 年在歐洲取得 CE 上市。
Third, we introduced the concept of developing public-private partnerships. While we have several of these partnerships already in place, in October, we disclosed an important long-term agreement with the Brazilian government for an exclusive recombinant Factor VIII hemophilia partnership to expand access and provide recombinant therapies to patients in Brazil, the third largest hemophilia market in the world.
第三,我們提出發展公私部門合作夥伴關係的概念。雖然我們已建立數項此類合作關係,但在 10 月,我們揭露了一項與巴西政府的重要長期協議:針對重組第八凝血因子(recombinant Factor VIII)的血友病獨家合作夥伴關係,以擴大可近性並向巴西病患提供重組療法;巴西是全球第三大血友病市場。
Lastly, we accelerated the pace of business development. We successfully integrated the Baxa, Synovis and SIGMA acquisitions. We entered into a collaboration with Onconova Therapeutics for European commercialization rights of rigosertib, a novel targeted anti-cancer compound. This will be an exciting addition to the portfolio, where we can leverage Baxter's legacy of treating critical diseases, existing leadership position in hematology and sales channel. We continue to advance our partnership with Momenta Pharmaceuticals during the year, as we've now selected three biosimilars targeted for the treatment of oncology, autoimmune and other inflammatory disorders. Finally, we announced a definitive agreement to acquire Gambro, a global innovator in hemodialysis and acute renal technologies. This acquisition enhances Baxter's competitive position by creating a global renal therapies business with a comprehensive product offering for both chronic and acute dialysis patients. This transaction also positions us to capitalize on the attractive fundamentals of the large and growing global dialysis products market and provides true strategic financial and operational synergies at attractive returns well in excess of our cost of capital.
最後,我們加快了業務發展的步伐。我們成功整合了 Baxa、Synovis 與 SIGMA 的收購案。我們與 Onconova Therapeutics 達成合作,取得 rigosertib(一種新型標靶抗癌化合物)在歐洲的商業化權利。這將為產品組合帶來令人振奮的新增項目,我們可運用百特在治療重大疾病方面的傳承、在血液學領域既有的領導地位以及銷售通路。我們在今年持續推進與 Momenta Pharmaceuticals 的合作夥伴關係,目前已選定三項生物相似藥(biosimilars),目標用於腫瘤、自體免疫及其他發炎性疾病的治療。最後,我們宣布已簽署確定性協議,將收購 Gambro——一家在血液透析與急性腎臟技術領域的全球創新者。此收購透過打造具完整產品組合的全球腎臟療法事業,服務慢性與急性透析病患,從而強化百特的競爭地位。此交易亦使我們得以把握龐大且持續成長的全球透析產品市場之有利基本面,並在具吸引力的報酬水準下,帶來真正具策略性的財務與營運綜效,其回報將遠高於我們的資本成本。
In summary, Baxter's portfolio remains strong. We continue to benefit from our focus on life saving therapies. The increased level of R&D investment over the years has transformed the new product pipeline into a robust portfolio of products and therapies that improve the quality of care and address key high potential areas of unmet medical need. We're committed to working with payers by establishing public and private partnerships, as we're well-positioned to provide solutions to their increasing challenges. We've executed on a number of business development opportunities that align with our core strengths and position Baxter for future success and accelerated growth. As always, I'd be happy to address any questions on these or other topics during the Q&A. So with that, I'd like to ask Bob to review the fourth quarter financial results and guidance for 2013. Then, I'll briefly come back to provide some additional perspectives. Bob?
總結而言,Baxter 的產品組合仍然強勁。我們持續受益於對救命療法的專注。多年來提高研發投資的水準,已將新產品管線轉化為強健的產品與療法組合,提升照護品質,並聚焦於具高潛力、尚未被滿足的醫療需求關鍵領域。我們致力於透過建立公私部門夥伴關係與付款方合作,因為我們具備優勢,能為其日益增加的挑戰提供解決方案。我們已執行多項與核心優勢一致的業務發展機會,使 Baxter 能在未來取得成功並加速成長。一如既往,我很樂意在問答環節就這些或其他主題回答任何問題。因此,接下來我想請 Bob 回顧第四季財務結果以及 2013 年的展望指引。之後,我會簡短回來補充一些觀點。Bob?
- CFO
- CFO
Thanks, Bob. Good morning, everyone. As Bob mentioned, earnings per diluted share in the fourth quarter, excluding special items, increased 8% to $1.26 per diluted share, which is at the higher end of our guidance range of $1.24 to $1.27 per diluted share. As we mentioned in the press release, GAAP results include after-tax special items of $206 million or $0.37 per diluted share. Approximately 65% of this charge is non-cash. The special items primarily include non-cash costs associated with the settlement of certain pension obligations in the US and business optimization initiatives pertaining to certain manufacturing and business operations around the world. These actions include the elimination of a number of positions as we continue to streamline our operations, rationalize our manufacturing footprint and optimize our general and administrative infrastructure. Annual savings are expected to total approximately $0.17 per share when fully implemented in 2015; however, for 2013, savings will equate to approximately $0.08 per diluted share, which is in addition to an incremental $0.05 of savings related to our actions implemented throughout 2012. We expect to reinvest a portion of these savings in promotional and marketing activities to support recent label expansions and upcoming new product launches on a global basis.
謝謝,Bob。各位早安。如 Bob 所提,第四季稀釋後每股盈餘(不含特殊項目)成長 8% 至每股 $1.26,位於我們每股 $1.24 至 $1.27 指引區間的高端。如我們在新聞稿中提到,GAAP 結果包含稅後特殊項目費用 $2.06 億,或每股稀釋後 $0.37。其中約 65% 為非現金項目。特殊項目主要包括與美國部分退休金義務結清相關的非現金成本,以及與全球特定製造與業務營運相關的業務優化措施。這些行動包括裁減若干職位,因為我們持續精簡營運、合理化製造據點布局,並優化一般與行政管理基礎架構。在 2015 年全面落實後,預期年度節省金額合計約為每股 $0.17;然而在 2013 年,節省金額約相當於每股稀釋後 $0.08,此外還加上我們於 2012 年期間所實施行動帶來的額外每股 $0.05 節省。我們預期將把部分節省金額再投資於推廣與行銷活動,以在全球範圍支持近期適應症標籤擴增及即將推出的新產品上市。
Now, let me briefly walk you through the P&L by line item for the fourth quarter and full year 2012, before turning to our financial outlook for 2013. Starting with sales, worldwide sales totaled approximately $3.8 billion in the fourth quarter and increased 4%. On a constant currency basis, revenues were in line with our guidance and increased 5%, driven primarily by strong growth in emerging markets and BioScience, which exhibited robust growth across all key product categories, particularly in the US. For the full year, worldwide sales increased 2% to $14.2 billion and after adjusting for foreign currency, sales advanced 5%.
現在,在談到 2013 年財務展望之前,我先簡要按損益表各項目帶各位回顧 2012 年第四季與全年表現。先從銷售額開始,第四季全球銷售額約為 $38 億,成長 4%。以固定匯率計,營收符合我們的指引並成長 5%,主要由新興市場與 BioScience 的強勁成長所帶動;BioScience 在所有主要產品類別均呈現穩健成長,尤其是在美國。全年而言,全球銷售額成長 2% 至 $142 億;若調整外匯影響,銷售額成長 5%。
In terms of individual business performance, global BioScience sales improved 7% to $1.7 billion in the fourth quarter. On a constant currency basis, sales advanced 9%, representing the strongest quarterly growth this year. For the full year, global BioScience sales increased 3% to $6.2 billion and after adjusting for foreign currency, sales rose 6%. Within the product categories, recombinant sales increased 1% to $581 million. On a constant currency basis, sales increased 3% as strong performance in the US with growth of 9% more than offset a decline in international sales primarily resulting from the planned impact of the Australian tender. Excluding the impact of tenders, global recombinant sales advanced 7% in the quarter. As Bob mentioned earlier, throughout 2012 we realized benefits associated with the new differentiated label of ADVATE, as we continue to drive conversion from plasma-derived therapies and competitive offerings and drive enhanced penetration of prophylactic treatment. This resulted in US recombinant growth of 10% for the full year, an accelerated level from what we've experienced in the last several years.
就各事業表現而言,第四季全球 BioScience 銷售額提升 7% 至 $17 億。以固定匯率計,銷售額成長 9%,為今年最強的單季成長。全年而言,全球 BioScience 銷售額成長 3% 至 $62 億;若調整外匯影響,銷售額成長 6%。在產品類別方面,重組產品銷售額成長 1% 至 $5.81 億。以固定匯率計,銷售額成長 3%;美國市場 9% 的強勁成長,足以抵銷國際銷售下滑,後者主要源於澳洲標案的既定影響。若排除標案影響,全球重組產品銷售額於本季成長 7%。如 Bob 先前提到,2012 年全年我們受益於 ADVATE 新的差異化標籤,並持續推動從血漿來源療法與競品的轉換,同時提升預防性治療的滲透率。這使得美國重組產品全年成長 10%,較我們過去數年的水準更為加速。
In antibody therapy, sales of $425 million increased 5% on both a reported and constant currency basis. This performance is a result of strong demand for GAMMAGARD LIQUID in the US, as we continue to promote awareness and diagnosis of primary immune deficiency and drive enhanced penetration of our Sub-Q therapy, given its favorable tolerability profile and low infusion site reaction rate. For the full year, antibody therapy sales advanced 5% on a constant currency basis. Excluding the benefit last year of approximately $100 million related to the absence of Octapharma, antibody therapy revenues advanced 12%. Moving on to plasma proteins, sales in the quarter were $447 million and increased 13% on both a reported and constant currency basis. This was due to strong double-digit growth of FEIBA and albumin, which offset lower plasma-derived Factor VIII sales in the US.
在抗體療法方面,銷售額為 $4.25 億,無論按報告口徑或固定匯率口徑皆成長 5%。此表現源於美國對 GAMMAGARD LIQUID 的強勁需求;我們持續提升對原發性免疫缺乏症的認知與診斷,並鑑於其良好的耐受性特徵與較低的注射部位反應率,推動我們皮下(Sub-Q)療法的更高滲透率。全年而言,抗體療法銷售額以固定匯率計成長 5%。若排除去年因 Octapharma 缺席所帶來約 $1 億的利益,抗體療法營收成長 12%。接著看血漿蛋白,本季銷售額為 $4.47 億,無論按報告口徑或固定匯率口徑皆成長 13%。這主要是 FEIBA 與白蛋白的強勁雙位數成長所致,抵銷了美國血漿來源第八凝血因子(Factor VIII)銷售下滑。
In the fourth quarter, sales in regenerative medicine advanced 20% to $180 million. After adjusting for foreign currency, sales rose 21%, driven by growth of TISSEEL and the benefit from the Synovis acquisition of approximately $25 million. Finally, revenues in the other category totaled $54 million in the quarter and increased 23%. Excluding foreign currency, sales increased 30%, driven primarily by milestone payments totaling approximately $20 million related to our ongoing collaborations with governments on the development of influenza vaccines.
第四季,再生醫學銷售額成長 20% 至 $1.80 億。若調整外匯影響,銷售額成長 21%,主要由 TISSEEL 的成長以及 Synovis 併購帶來約 $2,500 萬的貢獻所驅動。最後,其他類別本季營收合計 $5,400 萬,成長 23%。若排除外匯影響,銷售額成長 30%,主要由與各國政府就流感疫苗開發之持續合作所取得、合計約 $2,000 萬的里程碑款項所帶動。
In Medical Products, global sales in the fourth quarter totaled approximately $2.1 billion and increased 2%. On a constant currency basis, sales grew 3%. For the full year, Medical Product sales increased 1% to approximately $8 billion. After adjusting for foreign currency, sales increased 4%. Within the product categories, renal sales totaled $675 million and increased 2% on both a reported and constant currency basis. This was the result of ongoing PD penetration in emerging markets and accelerated patient gains in the US, as well as some one-time purchases by third parties totaling approximately $10 million. Sales in the global injectables category of $522 million increased 7%. On a constant currency basis, sales increased 8%. Performance continues to be driven by significant growth of certain injectable drugs and oncolytics like cyclophosphamide and growth in our international compounding business. IV Therapy sales advanced 7% to $500 million. After adjusting for foreign currency, sales rose 8%. This was due to increased demand for IV and Nutritional Therapies and incremental sales related to the Baxa acquisition of approximately $15 million.
在醫療產品(Medical Products)方面,第四季全球銷售額約為 $21 億,成長 2%。以固定匯率計,銷售額成長 3%。全年而言,醫療產品銷售額成長 1% 至約 $80 億。若調整外匯影響,銷售額成長 4%。在產品類別方面,腎臟相關銷售額為 $6.75 億,無論按報告口徑或固定匯率口徑皆成長 2%。這主要來自新興市場持續提升腹膜透析(PD)滲透率,以及美國病患數加速增加,並包含第三方一次性採購約 $1,000 萬。全球注射劑類別銷售額為 $5.22 億,成長 7%。以固定匯率計,銷售額成長 8%。表現持續由特定注射用藥與腫瘤用藥(如環磷醯胺)的顯著成長,以及我們國際調劑業務的成長所帶動。靜脈(IV)治療銷售額成長 7% 至 $5.00 億。若調整外匯影響,銷售額成長 8%。這主要由 IV 與營養療法需求增加,以及 Baxa 併購帶來約 $1,500 萬的增量銷售所致。
Infusion system sales totaled $210 million and were lower than the prior year by 11% on both a reported and constant currency basis. This was primarily due to the difficult comparison presented by the completed transition to the Spectrum pump in the US market. Finally, anesthesia posted sales of $140 million reflecting a decline of 5% on both a reported and constant currency basis. Double-digit growth across international markets was more than offset by lower sales in the US, which reflected fluctuations in purchasing patterns of US wholesalers. For the full year, anesthesia sales increased 3% on a constant currency basis.
輸注系統銷售額為 $2.10 億,無論按報告口徑或固定匯率口徑,均較去年下降 11%。這主要是因為美國市場已完成向 Spectrum 幫浦的轉換,使得比較基期較為不利。最後,麻醉產品銷售額為 $1.40 億,無論按報告口徑或固定匯率口徑皆下滑 5%。國際市場的雙位數成長,仍被美國銷售下滑所抵銷;美國下滑反映了美國批發商採購模式的波動。全年而言,麻醉產品銷售額以固定匯率計成長 3%。
Turning to the rest of the P&L, gross margin in the quarter of 52.4% improved sequentially by 30 basis points and reflects margin expansion of 60 basis points versus the prior year margin of 51.8%. This was a result of underlying operational expansion, driven primarily by the benefit of positive mix. This performance more than offset a number of headwinds including pension, amortization of intangible assets related to recent business development initiatives, and government austerity measures. For the full year, gross margin was 51.8%, which was 40 basis points higher than the 2011 gross margin of 51.4% and favorable to our full year guidance.
接著看損益表(P&L)的其餘部分,本季毛利率為 52.4%,較前一季提升 30 個基點,並較去年毛利率 51.8% 擴張 60 個基點。這主要是基礎營運擴張所致,主要受惠於有利的產品組合。此表現足以抵銷多項逆風因素,包括退休金、與近期業務發展計畫相關之無形資產攤銷,以及政府緊縮措施。全年毛利率為 51.8%,較 2011 年毛利率 51.4% 高出 40 個基點,且優於我們的全年指引。
SG&A totaled $810 million and increased 8% with 2 points of growth related to the inclusion of acquisitions. The remainder of the growth in the quarter is attributable to the impact of incremental pension expense and investments we are making in promotional and marketing initiatives and in international markets to enhance our global presence. In total, these items more than offset a benefit from foreign currency, aggressive management of discretionary spending and operational efficiencies derived from our process reengineering efforts. For the full year, SG&A increased 5%. Excluding expenses associated with acquisitions, which totaled approximately $80 million for the year, SG&A increased 2%.
銷售、一般及行政費用(SG&A)合計 8.10 億美元,成長 8%,其中 2 個百分點的成長與併購納入合併報表有關。本季其餘成長主要歸因於新增退休金費用的影響,以及我們在促銷與行銷計畫、以及國際市場上的投資,以提升全球能見度。整體而言,這些項目已超過外幣帶來的利益、對可自由裁量支出的積極管理,以及流程再造所帶來的營運效率提升之效益。全年 SG&A 增加 5%。若排除與併購相關的費用(全年約 8,000 萬美元),SG&A 增加 2%。
R&D spending in the fourth quarter increased 4% and totaled $263 million. Growth on a constant currency basis was in mid-single digits, reflecting the progress we are making in advancing a number of programs in our pipeline, including those in our leading hemophilia franchise, the Alzheimer's programs and our Phase III adult stem cell trial. R&D for the full year exceeded $1 billion, a record level for the Company. The operating margin in the quarter was 23.8%. For the full year, the operating margin was 22.9%. Interest expense was $22 million, compared to $15 million last year. This increase is due to incremental expense associated with the debt issuances earlier this year and lower interest income. Other income totaled $22 million in the quarter and is primarily attributable to a favorable foreign exchange impact on balance sheet positions. The tax rate was 21.7% for the quarter, which resulted in a year-to-date tax rate of 21.9%, in line with our guidance. Finally, as previously mentioned, adjusted EPS was $1.26 per diluted share, an increase of 8%. Adjusted EPS for the full year was $4.53, reflecting a 5% increase.
第四季研發(R&D)支出增加 4%,合計 2.63 億美元。以固定匯率計算的成長為中個位數,反映我們在推進多項研發管線計畫上的進展,包括我們領先的血友病產品線、阿茲海默症計畫,以及第三期成人幹細胞試驗。全年研發支出超過 10 億美元,創公司新高。本季營業利益率為 23.8%。全年營業利益率為 22.9%。利息費用為 2,200 萬美元,去年為 1,500 萬美元。此增加係因今年稍早發行債務所帶來的新增費用,以及利息收入下降。本季其他收益合計 2,200 萬美元,主要歸因於外匯對資產負債表部位的有利影響。本季稅率為 21.7%,使年初至今稅率為 21.9%,符合我們的指引。最後,如先前所述,調整後每股盈餘(EPS)為每股稀釋後 1.26 美元,成長 8%。全年調整後 EPS 為 4.53 美元,反映 5% 的成長。
Turning to cash flow. Cash flow from operations in the quarter totaled $945 million. On a year-to-date basis, cash flow from operations exceeded $3.1 billion, an improvement of 10% year-over-year. Capital expenditures in 2012 totaled $1.2 billion resulting in free cash flow of $1.9 billion. DSO ended the quarter at 53.3 days comparable to last year and reflecting a 4-day improvement versus last quarter. Inventory turns of 2.5 improved versus the third quarter, but are lower than turns of 2.7 last year, due to the impact of recent acquisitions and increased inventory levels to support late stage clinical trials and growing demand. Lastly, for 2012, we repurchased 25 million shares for $1.5 billion or on a net basis 15 million shares for approximately $1 billion, in line with our full year objective.
接著談現金流。本季營運活動產生的現金流量合計 9.45 億美元。以年初至今計算,營運活動現金流量超過 31 億美元,年增 10%。2012 年資本支出合計 12 億美元,因而自由現金流為 19 億美元。應收帳款週轉天數(DSO)季末為 53.3 天,與去年相當,並較上季改善 4 天。存貨週轉率 2.5 較第三季改善,但低於去年 2.7,主要因近期併購影響,以及為支援後期臨床試驗與成長中的需求而提高存貨水位。最後,2012 年我們回購 2,500 萬股、金額 15 億美元;或以淨額計回購 1,500 萬股、約 10 億美元,符合我們的全年目標。
Finally, let me conclude my comments this morning by providing our financial outlook for the full year 2013. As you saw in the press release, we expect earnings of $4.60 to $4.70 per diluted share. This includes the impact of the Gambro acquisition, which is projected to close at the end of the second quarter with estimated dilution of $0.10 to $0.15 per diluted share. The dilution is primarily related to non-cash amortization of intangible assets, which will be finalized upon closing. By line item of the P&L and starting with sales, we expect sales growth excluding the impact of foreign currency of approximately 10%. This includes a half year sales contribution from Gambro of approximately $830 million. Excluding Gambro, Baxter sales growth on a constant currency basis is expected to be approximately 4%. Given our current outlook for foreign exchange rates, we do not expect foreign currency to materially impact sales growth.
最後,讓我在今天上午以提供 2013 全年財務展望來結束我的評論。如同你們在新聞稿中所見,我們預期每股稀釋後盈餘為 4.60 至 4.70 美元。此包含 Gambro 併購案的影響,預計於第二季末完成交割,估計將造成每股稀釋後 0.10 至 0.15 美元的稀釋。該稀釋主要與無形資產的非現金攤銷有關,並將於交割時最終確定。就損益表各項目而言,先從營收開始,我們預期在排除外幣影響後,營收成長約 10%。其中包含 Gambro 半年營收貢獻約 8.30 億美元。若排除 Gambro,Baxter 以固定匯率計算的營收成長預期約 4%。依我們目前對匯率的展望,我們不預期外幣會對營收成長造成重大影響。
For the full year, we expect gross margin for the Company to be 100 to 120 basis points lower than the gross margin in 2012 of 51.8%. While we expect margin expansion of approximately 100 basis points in the base Baxter business as a result of positive mix benefits, we expect this to be more than offset by intangible asset amortization related to Gambro, incremental pension expense, government austerity measures, the medical device tax and foreign currency. In terms of expenses, we expect SG&A to increase approximately 10% and R&D to grow in mid-single digits both reflecting the addition of Gambro. We expect interest expense to total approximately $170 million, reflecting the impact of a new $3 billion debt issuance related to the acquisition. We expect other to be an expense of approximately $20 million to $30 million.
就全年而言,我們預期公司毛利率將較 2012 年的 51.8% 低 100 至 120 個基點。雖然我們預期 Baxter 基礎業務因有利的產品組合效益而帶來約 100 個基點的毛利率擴張,但預期將被與 Gambro 相關的無形資產攤銷、新增退休金費用、政府緊縮措施、醫療器材稅以及外幣因素所抵銷且超過。就費用而言,我們預期 SG&A 約增加 10%,研發(R&D)以中個位數成長,兩者皆反映納入 Gambro。我們預期利息費用合計約 1.70 億美元,反映為該併購而新增發行 30 億美元債務的影響。我們預期其他項目將為約 2,000 萬至 3,000 萬美元的費用。
Although, over the long range plan, we expect the tax rate to drift upwards to approximately 23%, in 2013, we expect a tax rate of approximately 22%. We also expect a full year average share count of approximately 550 million shares, which assumes approximately 300 million in net share repurchases. From a cash flow perspective, we plan to generate cash flow from operations of approximately $3.3 billion and expect capital expenditures to total approximately $1.7 billion, which includes Gambro and the investments we are making to enhance our plasma manufacturing footprint in Covington, Georgia.
雖然在長期計畫期間,我們預期稅率將逐步上升至約 23%,但在 2013 年,我們預期稅率約為 22%。我們亦預期全年平均流通股數約 5.50 億股,此假設包含淨回購約 3.00 億美元的股份。就現金流角度而言,我們計畫產生約 33 億美元的營運活動現金流量,並預期資本支出合計約 17 億美元,其中包含 Gambro,以及我們為強化喬治亞州科溫頓(Covington, Georgia)血漿製造布局所進行的投資。
Moving to sales and our assumptions for Medical Products and BioScience in the major product categories. Recall that in 2013, we're moving to a new franchise reporting structure; therefore, providing guidance in the new format this morning. For your convenience, we've posted the historical restated sales, including 2012 by quarter to the Investor Relations section of our website.
接著談醫療產品(Medical Products)與生物科學(BioScience)在主要產品類別的營收,以及我們的假設。請記得在 2013 年,我們將改採新的事業群(franchise)揭露架構;因此,今天上午將以新格式提供指引。為方便各位,我們已將歷史重編後的營收(包含 2012 年按季度)公布於我們網站的投資人關係(Investor Relations)專區。
Now, beginning with Medical Products on a constant currency basis, including the half year contribution related to Gambro, we expect sales growth in the low teens. Excluding Gambro, we expect sales for Medical Products to grow 3% to 4%. Specifically we expect Baxter Renal sales, which totaled $2.5 billion in 2012 to grow in low-single digits driven by mid-single digit growth in PD and lower HD revenues. As mentioned earlier, the base business sales will be augmented by Gambro and a half year sales contribution totaling approximately $830 million. We expect fluid system sales, which includes IV solutions, infusion pumps and access sets to grow in mid-single digits. 2012 sales for this category were $2.9 billion. We expect specialty pharma sales, which includes our nutritional therapies and inhaled anesthetics to also grow in mid-single digits. 2012 sales for this category were $1.5 billion. We expect our biopharma solutions business to record comparable sales to 2012 of approximately $1 billion.
現在,先從醫療產品(Medical Products)以固定匯率計算開始,包含 Gambro 半年貢獻在內,我們預期營收成長為低十位數百分比。若排除 Gambro,我們預期醫療產品營收成長 3% 至 4%。具體而言,我們預期 Baxter 腎臟照護(Renal)營收(2012 年合計 25 億美元)將呈低個位數成長,動能來自腹膜透析(PD)的中個位數成長,以及血液透析(HD)營收較低。如先前所述,基礎業務營收將由 Gambro 挹注,半年營收貢獻合計約 8.30 億美元。我們預期輸液系統(fluid system)營收(包含靜脈注射溶液 IV solutions、輸注幫浦 infusion pumps 與導管/連接套組 access sets)將以中個位數成長。此類別 2012 年營收為 29 億美元。我們預期專科藥品(specialty pharma)營收(包含營養治療與吸入式麻醉劑)亦將以中個位數成長。此類別 2012 年營收為 15 億美元。我們預期生物製藥解決方案(biopharma solutions)業務的營收將與 2012 年相當,約 10 億美元。
For BioScience, we currently project sales growth on a constant currency basis in the 4% to 5% range. Our outlook includes low to mid-single digit growth in our hemophilia franchise, which includes recombinant and plasma-derived Factor VIII and Factor IX therapies and FEIBA and inhibitor therapy. This franchise posted sales of $3.2 billion in 2012. We expect mid to high single-digit growth in biotherapeutics, where sales totaled more than $2.1 billion in 2012. This growth will be driven primarily by strong demand for immunoglobulin therapies including GAMMAGARD LIQUID and Sub-Q therapies, as well as growth in albumin and our treatments for Alpha-1 deficiency.
就BioScience而言,我們目前以固定匯率基礎預估銷售成長約在4%至5%區間。我們的展望包含血友病事業的低至中個位數成長,該事業包括重組與血漿來源的第VIII因子與第IX因子療法,以及FEIBA與抑制物治療。該事業於2012年的銷售額為32億美元。我們預期生物治療(biotherapeutics)將有中至高個位數成長,2012年銷售總額超過21億美元。此成長主要將由免疫球蛋白療法(包括GAMMAGARD LIQUID與皮下(Sub-Q)療法)的強勁需求所帶動,並加上白蛋白以及我們針對Alpha-1缺乏症的治療之成長。
In BioSurgery, we expect high single digit growth. Sales in this category totaled $673 million in 2012. Finally, we expect our vaccine franchise, which recorded sales of $254 million in 2012, to grow in mid-single digits. As mentioned in our press release, for the first quarter, we expect earnings per diluted share of $1.03 to $1.05 and sales growth, excluding the impact of foreign currency, of 2% to 3%. Based on our outlook for foreign exchange rates, we do not expect foreign currency to meaningfully impact sales growth in the first quarter. Thanks. Now, let me turn the call back over to Bob.
在BioSurgery方面,我們預期將有高個位數成長。此類別2012年的銷售總額為6.73億美元。最後,我們預期疫苗事業(2012年銷售額為2.54億美元)將以中個位數成長。如同我們在新聞稿中提到的,第一季我們預期稀釋後每股盈餘為1.03至1.05美元,且在排除外幣影響後的銷售成長為2%至3%。基於我們對外匯匯率的展望,我們不預期外幣會在第一季對銷售成長造成顯著影響。謝謝。現在,讓我把電話交回給Bob。
- Chairman & CEO
- Chairman & CEO
Thanks, Bob. In closing, I'm very pleased with the progress that we made in 2012 financially, operationally and strategically. We achieved sales and adjusted earnings per diluted share growth of 5%, as we continued to respond to an evolving and demanding environment. We generated strong, sustainable cash flow of more than $3.1 billion, increased our dividend by 34% and returned significant value to our shareholders. We strengthened our core portfolio and meaningfully advanced our new product pipeline, that's as strong today as at any time in our history. We executed on a number of collaborations and business development initiatives that complement our current businesses, leverage our capabilities and provide enhanced growth in the future.
謝謝,Bob。在結語中,我對我們在2012年於財務、營運與策略面所取得的進展感到非常滿意。在我們持續因應不斷演變且要求更高的環境之際,我們達成了銷售與調整後稀釋後每股盈餘各5%的成長。我們創造了超過31億美元強勁且可持續的現金流,將股利提高34%,並為股東回饋了可觀價值。我們強化了核心產品組合,並大幅推進新產品研發管線,其強度在今日不亞於我們歷史上的任何時期。我們執行了多項合作與業務發展計畫,這些計畫可補強我們現有業務、發揮我們的能力,並在未來帶來更高的成長。
I remain very confident in the long-term growth prospects for our Company, which we laid out in detail, late last year at our investor conference in Chicago. Our entire Management team remains committed to enhancing shareholder value in the coming years, as we implement our strategies, deliver on our commitments and more importantly, meet the needs of the patients and customers that utilize our products to save and sustain lives. Thank you. With that, let's open up the call to Q&A.
我仍對本公司長期成長前景非常有信心;我們已於去年稍晚在芝加哥的投資人會議中詳細說明。我們整個管理團隊仍致力於在未來幾年提升股東價值,透過落實我們的策略、履行我們的承諾,更重要的是,滿足使用我們產品以拯救並維持生命之病患與客戶的需求。謝謝。接下來,我們開放問答。
Operator
Operator
(Operator Instructions)
(接線員指示)
I would like to remind participants that this call is being recorded. A digital replay will be available on the Baxter International website for 30 days at www.baxter.com. David Lewis, Morgan Stanley.
提醒各位與會者,本次電話會議將被錄音。數位重播將於Baxter International網站提供30天,網址為www.baxter.com。Morgan Stanley的David Lewis。
- Analyst
- Analyst
Bob, obviously there's a lot of reclassification with the new reporting structure. I wondered just -- if you could just -- a high level commentary, if year-on-year core Baxter is slowing incrementally just a little bit into 2013? Just maybe give us some high level commentary on some of the significant headwinds and tailwinds to growth. Obviously, there's incrementally more headwinds in 2013. And what some of those are?
Bob,顯然在新的報導架構下有很多重新分類。我想請教——如果可以的話——就高層次評論一下,核心Baxter的年對年成長在進入2013年時是否只是略為逐步放緩?也請就一些重要的成長逆風與順風做個高層次說明。顯然2013年的逆風會逐步增加。其中有哪些因素?
- CFO
- CFO
Yes, sure, David. So a couple things. I would say in 2012, we benefited from the acquisitions of Synovis and Baxa, which are now fully in our base. As you rightly point out, we are facing some headwinds here as we go into 2013. Starting with government austerity measures, which we project a total, approximately, $90 million which includes approximately $30 million for the US Medical Device Tax, which we are putting through sales and margin. The other $60 million relates to a combination of austerity measures in Europe, but also in Asia Pacific, particularly in China as well. So an even larger austerity impact this year than what we've seen in the last couple of years.
好的,當然可以,David。有幾點。我會說,2012年我們受惠於Synovis與Baxa的併購,現在它們已完全納入我們的基期。如你所指出的,進入2013年我們確實面臨一些逆風。首先是政府的撙節措施,我們預估合計約9,000萬美元,其中約3,000萬美元來自美國醫療器材稅,我們會反映在銷售與利潤率上。另外6,000萬美元則與歐洲的撙節措施組合有關,同時也包括亞太地區,尤其是中國。因此,今年的撙節影響甚至比過去幾年所見更大。
I would also just remind everyone, we will remain constrained for plasma production here in 2013, as we work through bringing the old LA facility back online and ramp up our new LA and [re-etty] facilities, but that is definitely on track. We should have increasing product availability throughout the course of the year. So, the other thing I would mention is, we are going to anniversary some of the recombinant Factor VIII tender impact related to Australia, but that doesn't really happen until the middle of the year. So in particular, as you look at our guidance for the first quarter, the plasma product constraints are most acute for us in the first quarter. We have increasingly robust supply as we move throughout the year. As I mentioned, we don't anniversary the Australia tender impact until the middle of the year.
我也想提醒大家,2013年我們的血漿產能仍將受限,因為我們正在推動讓舊的洛杉磯(LA)廠重新上線,並提升我們新的LA與[re-etty]廠的產能爬坡,但這些都確實按計畫進行。我們預期在全年過程中產品供應量會逐步增加。另外我會提到的是,我們將迎來與澳洲重組第VIII因子標案影響相關的比較基期(anniversary),但那要到年中才會發生。因此,特別是當你看我們第一季的指引時,血漿產品供應受限對我們的影響在第一季最為明顯。隨著年度推進,我們的供應將愈來愈充足。如我所提到的,澳洲標案影響要到年中才會進入比較基期。
The austerity measures that I mentioned are impacted immediately as we begin the year. What's going to accelerate growth from the 2% to 3% that we've got in the first quarter as we move towards approximately 4% for the full year, relates to a couple of things. One of which is, the timing of tenders, particularly in plasma-derived products such as FEIBA and plasma-derived Factor VIII. Those are more concentrated in the second and third quarter than they've been in prior years. We do expect to begin to start shipping to Brazil related to recombinant Factor VIII in the second quarter, as well. As I mentioned, an increased product availability throughout the course of the year on the plasma-derived side will also help us drive accelerated growth beyond the first quarter.
我剛提到的撙節措施在年初一開始就會立即產生影響。至於是什麼因素會讓我們從第一季的2%至3%成長,加速到全年約4%的成長,主要與幾件事有關。其中之一是標案時點,特別是在FEIBA與血漿來源第VIII因子等血漿來源產品。這些標案相較於過去年度更集中在第二與第三季。我們也預期將在第二季開始出貨至巴西,與重組第VIII因子相關。如我所提到的,血漿來源產品在全年供應量的增加,也將協助我們推動超越第一季的加速成長。
- Analyst
- Analyst
Okay. Very helpful. Maybe just a follow-up on some of the key growth drivers we saw in 2012. Then maybe a continuation to 2013. So, the first obviously, is the Recombinant franchise in the US, I think actually accelerated again in the fourth quarter on a comp adjusted basis. So when you think about the prophy label -- for either Bob -- prophy label, plus the higher dosing, what do you think the trend line is for US Recombinants heading into 2013? Then, the IVIG business obviously stronger US, weaker OUS as you've been prioritizing in 2012. When do you see that basing out in 2013? Is there any evidence that the reduced supply in Europe is beginning to have an impact on pricing in Europe for IVIG? Thank you.
好的。非常有幫助。也許再追問一下我們在2012年看到的一些關鍵成長動能,以及延續到2013年的情況。首先很明顯的是,美國的重組產品事業,我認為在第四季以調整後的可比基礎來看其實又再加速。因此當你思考預防性(prophy)適應症標示——不論是Bob——預防性標示,加上更高劑量使用,你認為美國重組產品在進入2013年時的趨勢線會是如何?另外,IVIG業務顯然在美國較強、在美國以外(OUS)較弱,因為你們在2012年一直在做優先排序。你們預期2013年何時會觸底並趨於穩定?是否有任何跡象顯示,歐洲供應減少正開始對歐洲IVIG的定價造成影響?謝謝。
- CFO
- CFO
Yes, I'll handle the IVIG one first. I would say we've largely made the move that we're going to make in terms of product shift by the end of 2012 here. So 2013, we're going to be operating at a similar level to what we're exiting 2012 at. That does provide a little bit of benefit year-over-year in the first quarter or two, but that's largely played out, in terms of the shift. In terms of pricing, the markets that we continue to participate in Western Europe -- I would say that, we haven't seen any significant impact one way or the other on price at this point. Then as it relates to recombinant Factor VIII --
好的,我先回答IVIG的部分。我會說,就產品轉移而言,我們在2012年底前大致已完成我們要做的調整。因此在2013年,我們的營運水準將與2012年底的退出水準相近。這在第一季或前兩季的年對年比較上會帶來一些助益,但就轉移本身而言,基本上已大致反映完畢。至於定價,我們持續參與的西歐市場——我會說,到目前為止我們尚未看到價格在任何方向上有顯著影響。至於重組第VIII因子——
- Chairman & CEO
- Chairman & CEO
David, Ludwig Hantson is with us this morning. Ludwig, why don't you just take a minute and maybe update the callers on what's going on with the whole uptake on prophylaxis in the US, because obviously we're experiencing some very encouraging results.
David,Ludwig Hantson 今早與我們同在。Ludwig,你何不花一分鐘,向來電者更新一下美國在預防性治療(prophylaxis)整體採用情況的進展,因為顯然我們正看到一些非常令人鼓舞的結果。
- President - Biosciences
- President - Biosciences
Yes. So thanks, Bob. Thanks for the question. So yes, this is a success. We've got the label about a year ago. So we are one year into the launch for ADVATE prophy. It's a success from a -- I would say from a -- first of all, from the patient perspective. Unmet medical needs are still high. We still have a lot of patients who are on the [NAMD] so we're switching over. When you look at the number of patients that were switched over to a prophy regimen, we're talking about more than 200 patients. We are looking at continuing that trend into 2013, so clearly we're moving into 2013 with a strong momentum. Having said that, we're also aware of the fact that we might get competition by the end of 2013 into this space which might slow us down a little bit. But overall, we believe that we will continue to grow ADVATE in 2013 and then moving forward. Then maybe bridging also to FEIBA, since it is in the same space. You might have seen the fact that we got our prophy results for FEIBA. We are moving towards a BLA submission first quarter of 2013 in the US. We already have the indication in Europe in the majority of the countries, so you will see that by the end of this year, when we get the approval in the US, an increased focus on moving our FEIBA patients to a prophy regimen.
是的。所以謝謝你,Bob。謝謝這個問題。所以是的,這是一項成功。我們大約一年前拿到標籤核准。因此 ADVATE 預防用藥(ADVATE prophy)上市已滿一年。這是一項成功——我會說——首先,從病患角度來看。未被滿足的醫療需求仍然很高。我們仍有很多病患使用 [NAMD],因此我們正在進行轉換。當你看轉換到預防性療程(prophy regimen)的病患數量時,我們談的是超過 200 位病患。我們預期這個趨勢會延續到 2013 年,因此很明顯我們帶著強勁動能進入 2013 年。話雖如此,我們也意識到,2013 年底可能會有競品進入這個領域,這可能會讓我們的速度稍微放慢一些。但整體而言,我們相信 2013 年 ADVATE 仍會持續成長,並在之後繼續向前。接著也許連結到 FEIBA,因為它在同一個領域。你可能已看到我們取得 FEIBA 的預防性治療結果。我們正朝向在美國於 2013 年第一季提交 BLA 申請。我們在歐洲多數國家已經有該適應症,因此你會看到在今年底、當我們在美國獲得核准時,將更聚焦於把我們的 FEIBA 病患轉到預防性療程。
- Chairman & CEO
- Chairman & CEO
Is that helpful, David?
David,這樣有幫助嗎?
- Analyst
- Analyst
Perfect.
非常好。
Operator
Operator
Larry Keusch, Morgan Keegan.
Larry Keusch,Morgan Keegan。
- Analyst
- Analyst
Oops, wrong firm. Just a couple of quick ones. Bob, you've obviously done a bunch on the business development side in 2012. Just wanted to gain a little sense of your appetite for M&A as you go forward. Does the integration of Gambro hold you back a little bit? How do you think about that?
喔,搞錯公司了。我有幾個簡短的問題。Bob,你在 2012 年顯然在業務發展(business development)方面做了不少。我想稍微了解一下你們未來對併購(M&A)的意願。Gambro 的整合會不會在某種程度上讓你們綁手綁腳?你們怎麼看這件事?
- Chairman & CEO
- Chairman & CEO
Well, obviously given the magnitude of the Gambro deal, Larry, yes, it's going to limit us a little bit for awhile. But I would say, as opportunities arise, the smaller kind of bolt-on things that we've done more of over the last couple of years, we're certainly in a position to continue to do that. I mean I actually couldn't be more pleased with the progress and the momentum on the BD front over the last two years in the Company. I think we've done a lot of good stuff. The smaller deals we've done have, I think, helped us develop competencies in terms of how you integrate and so on. So I think we're very well-positioned once we manage through the anti-trust process and close the Gambro deal to move ahead and integrate Gambro. But no, we continue to be very open-minded and receptive to BD things that emerge, one of which, actually we just announced this morning. I don't know if you had a chance to see it, that came across the wire, which was to acquire some hemophilia assets from Ipsen Pharma. So that's representative of the kind of thing we're going to continue to do.
嗯,Larry,顯然以 Gambro 交易的規模來看,是的,它會在一段時間內稍微限制我們。但我會說,當機會出現時,像我們過去幾年做得比較多的那種較小型的補強式收購(bolt-on),我們當然仍有條件繼續進行。我的意思是,我其實對公司過去兩年在 BD 方面的進展與動能感到非常滿意。我認為我們做了很多很好的事情。我們做的較小型交易,我想,已幫助我們在整合方式等方面建立能力。因此我認為,一旦我們完成反托拉斯程序並完成 Gambro 交易交割,我們就能非常有利地繼續往前並整合 Gambro。但不,我們仍會對出現的 BD 機會保持非常開放的心態並樂於接受,其中之一其實就是我們今天早上剛宣布的。我不知道你是否有看到那則新聞稿——剛剛在媒體上發布——內容是收購 Ipsen Pharma 的一些血友病資產。所以這正代表我們將持續進行的那類型交易。
- CFO
- CFO
Larry, I would just add that given how we're financing the Gambro acquisition and the structure of that and the use of offshore cash, while it is a significant acquisition; it is going to allow us to position ourselves to maintain some strategic flexibility going forward here as well.
Larry,我只想補充一下,考量我們為 Gambro 收購案的融資方式、其結構,以及對海外現金的運用,雖然這是一筆重大收購;但它也將使我們在未來仍能維持一定的策略彈性。
- Analyst
- Analyst
Okay, terrific. Then just a quick one, just because I wanted to revisit it. With the approval of ADVATE in China -- I know this is going to be a longer term process, but how should we think about what steps need to occur before that becomes a meaningful driver of revenues for you guys? Because it would certainly seem to be a big opportunity.
好的,很棒。那再一個簡短問題,因為我想再回到這點。隨著 ADVATE 在中國獲批——我知道這會是較長期的過程——但在它成為你們營收的重要驅動因素之前,我們應該如何看待需要發生哪些步驟?因為這看起來確實是一個很大的機會。
- Chairman & CEO
- Chairman & CEO
Well, it is, Larry. But obviously, given the different market dynamics the adoption on that is going to be somewhat slow. But we're excited about the longer term opportunity. I think we have to be realistic in terms of the adoption curve. We look for ways to leverage our other hemophilia assets as well in China. As we've talked before, this is a very large market, largely untreated and undiagnosed. Besides launching ADVATE more broadly, this is about leveraging our emerging broader portfolio from plasma-derived to Recombinant to ADVATE to the other products that are being approved, because it's critical for us to establish a leadership position and maintain that in China for the long-term benefit. I don't know -- Ludwig, if there's anything you want to add to that?
嗯,確實如此,Larry。但顯然,鑑於不同的市場動態,其採用速度會相對較慢。不過我們對長期機會感到興奮。我認為我們必須對採用曲線保持務實。我們也在尋找方法,在中國同時槓桿運用我們其他血友病資產。如同我們之前談過的,這是一個非常大的市場,但多數仍未治療且未被診斷。除了更廣泛地推出 ADVATE 之外,這也關乎於運用我們正在形成的更完整產品組合——從血漿來源(plasma-derived)到重組(Recombinant)到 ADVATE,再到其他正在獲批的產品——因為對我們而言,建立並長期維持在中國的領導地位至關重要。我不知道——Ludwig,你是否想補充?
- President - Biosciences
- President - Biosciences
Yes. I'd like to add the following. So if you look at the BRIC countries, you're talking about more than 1 million activity units. When you bring it down, most of these patients are being treated with plasma device products. So there is a great opportunity in each of these countries to convert from plasma to recombinant, but also increase the diagnosis rate. I would say, the bigger ones are clearly Russia and Brazil. So you're aware of the fact that, we have an agreement with the Ministry of Health and Hemobras in Brazil. Bob mentioned that, we will start shipping product -- our plan is to start shipping product to Brazil second quarter of this year. We also have a regulatory strategy to penetrate Russia, which we're also working towards approval this year. Then China is the third one, so clearly it's bigger than China. So we have growth opportunities in this business that clearly will continue to help us move ADVATE and hemophilia forward.
是的。我想補充如下。如果你看 BRIC 國家,你談的是超過 100 萬個活性單位(activity units)。再細分下來,這些病患多數是以血漿來源產品治療。因此在每個國家都有很大的機會,將治療從血漿來源轉換到重組產品,同時也提高診斷率。我會說,較大的市場顯然是俄羅斯和巴西。你也知道,我們在巴西與衛生部以及 Hemobras 有一項協議。Bob 提到,我們的計畫是在今年第二季開始向巴西出貨產品。我們也有一套法規策略來打入俄羅斯市場,目前也正朝著今年取得核准努力。接著中國是第三個,所以很明顯這不只是中國。因此,我們在這項業務上有成長機會,這些機會顯然將持續幫助我們推動 ADVATE 與血友病業務向前。
- Analyst
- Analyst
Okay, terrific.
好的,很棒。
- Corporate VP - IR
- Corporate VP - IR
Larry, it's Mary Kay. I would just add that, while we have approval in China, we haven't received reimbursement approval. So we actually haven't launched. We will launch in 2013.
Larry,我是 Mary Kay。我只想補充,雖然我們在中國已獲批,但尚未取得納入給付(reimbursement)核准。所以我們其實還沒有上市。我們將在 2013 年上市。
Operator
Operator
Mike Weinstein, JPMorgan.
Mike Weinstein,摩根大通(JPMorgan)。
- Analyst
- Analyst
Could you spend a minute on the agreement this morning to acquire the Inspiration assets? Maybe just walk through where you think that program fits in relative to FEIBA? Maybe just give us your thoughts as well as in terms of the clinical profile of that product relative to FEIBA? Thanks.
你能否花一點時間談談今天早上收購 Inspiration 資產的協議?也許請你說明一下,你認為該項目相對於 FEIBA 的定位在哪裡?也請分享你對該產品相對於 FEIBA 的臨床特性(clinical profile)的看法?謝謝。
- Chairman & CEO
- Chairman & CEO
Yes. So Mike, I'm going to ask Ludwig to address specific clinical application of the products, where they fit more broadly in our hemophilia strategy. Then, maybe Bob Hombach can briefly comment on some of the financial aspects. Although, I think it was pretty clearly detailed in our press release. So, Ludwig, if you go ahead and give a response --
好的。所以 Mike,我會請 Ludwig 回答產品的具體臨床應用,以及它們在我們更廣泛的血友病策略中的定位。接著也許 Bob Hombach 可以簡要評論一些財務面向。不過我想我們在新聞稿中已經寫得相當清楚。所以,Ludwig,你先回應——
- President - Biosciences
- President - Biosciences
Yes. So, maybe first thing is, we are excited about this opportunity. We believe this is a great fit with our current portfolio and with our pipeline. It is the late stage, it's a Phase III asset in an unmet medical need. So the asset itself, so OBI-1, this is a recombinant forcing Factor VIII, which is being investigated for the treatment of acquired Hemophilia A and Hemophilia A with inhibitors. The profile of the molecule may help unmet needs that persist in the treatment of hemophilia. Specifically, in the management of bleeds in patients who have acquired Hemophilia A. So this is different than what we have with FEIBA. FEIBA -- so OBI-1 versus FEIBA, those two products have unique product profiles and potential applications.
是的。所以,或許第一點是,我們對這個機會感到振奮。我們相信這與我們目前的產品組合以及研發管線非常契合。這是後期階段,是一個針對未被滿足醫療需求的第三期(Phase III)資產。就該資產本身而言,OBI-1 是一種重組豬源第八凝血因子(Factor VIII),目前正在研究用於治療後天性 A 型血友病,以及合併抑制物的 A 型血友病。該分子的特性可能有助於解決血友病治療中仍然存在的未滿足需求。具體而言,是在管理後天性 A 型血友病患者的出血方面。因此這與我們的 FEIBA 不同。FEIBA——也就是 OBI-1 相對於 FEIBA,這兩項產品具有獨特的產品特性與潛在應用。
When you look at the difference between those two indications from a patient perspective, clearly, acquired Hemophilia A is a very rare to a potentially life threatening breathing disorder. It's estimated that 1.5 cases per million lives annually. It is caused by the development of inhibitors. Different from congenital hemophilia, acquired hemophilia is typically a disorder of all of adults and occurs equally in both males and females. So clearly, different from the space that we're in now with ADVATE and with FEIBA. We look at the pattern of bleeding, it is also different. Those people come in to the hospital. They typically bleed in the skin, the muscles, the soft tissue, as opposed to bleeding into the joints. So I think my message is that, the patient segmentation is different. The market segmentation is different. The strategy is complimentary to what we have with FEIBA and ADVATE. We're looking at this as a great addition to our portfolio. With respect to the financials, Bob?
從病患角度來看,當你比較這兩個適應症的差異時,很明顯,後天性 A 型血友病是一種非常罕見、且可能危及生命的出血性疾病。估計每年每百萬人口約 1.5 例。其成因是抑制物的產生。不同於先天性血友病,後天性血友病通常是成人疾病,且男女發生率相同。因此,這顯然不同於我們目前在 ADVATE 與 FEIBA 所處的領域。我們看出血型態,也有所不同。這些病人會進到醫院。他們通常出血在皮膚、肌肉、軟組織,而不是關節內出血。所以我想要傳達的是,病患分群不同。市場分群不同。策略上與我們現有的 FEIBA 與 ADVATE 互補。我們把它視為對我們產品組合的一項很好的補充。至於財務方面,Bob?
- CFO
- CFO
Yes, I would just say that, we've structured this deal as we have many other deals in that we're paying primarily for success here. So the milestones are tied to approval. Then additional milestones assuming we achieve certain sales levels going forward here. So we're pleased with how the structure is set up. From a sales contribution standpoint, while this is late stage, it does have orphan drug designation and fast track status. It will take a bit of time to ramp up sales, so I would say over our LRP here, it would be a modest contributor to the top line. But beyond our LRP and over time, this -- assuming we get multiple indications here, could be more than a $200 million product for us.
是的,我只想說,我們把這筆交易的架構設計得和許多其他交易一樣:主要是為成功付費。因此,里程碑付款與核准掛鉤。接著,若未來達到特定銷售水準,還會有額外里程碑。所以我們對這個架構安排感到滿意。從銷售貢獻的角度來看,雖然這是後期資產,但它具有孤兒藥資格與快速通道(fast track)身分。銷售爬坡需要一些時間,因此我會說在我們的 LRP 期間,它對營收(top line)的貢獻會是溫和的。但在我們的 LRP 之後、隨著時間推進——假設我們取得多個適應症——它對我們而言可能會成為一個超過 2 億美元的產品。
- President - Biosciences
- President - Biosciences
So the timeline -- so we're looking at a potential submission later this year. FDA will decide how fast they want to move. But, this is orphan drug and got fast track. So difficult to comment on the launch, but the impact will be more in 2015 than in 2014.
至於時程——我們預計可能在今年稍晚提出申請。FDA 會決定他們想以多快的速度推進。不過,這是孤兒藥且已取得快速通道。因此很難評論上市時間,但其影響會更多落在 2015 年而非 2014 年。
- Chairman & CEO
- Chairman & CEO
Okay, Mike does that -- is that helpful?
好的,Mike,這樣——有幫助嗎?
- Analyst
- Analyst
Yes, that was helpful. So let me switch to just another pipeline asset then.
有,這很有幫助。那我再切換到另一個研發管線資產。
- Chairman & CEO
- Chairman & CEO
Sure.
當然。
- Analyst
- Analyst
The partnership with Onconova. Could you just spend a minute on the MDS trial design and just the expectations for when that would reach its crossover point in that Phase III trial? When we would see a read out from that?
與 Onconova 的合作。你能否花一點時間談談 MDS 試驗設計,以及在那項第三期試驗中預期何時會到達交叉(crossover)點?我們何時會看到讀出(read out)結果?
- Chairman & CEO
- Chairman & CEO
Okay, Ludwig?
好的,Ludwig?
- President - Biosciences
- President - Biosciences
Great. So, we're also excited about this one, so you see there's a lot of stuff going on in 2013. So they have three programs -- or we have three programs. One is an IV program in high-risk MDS patients. The second program is an oral program in low-risk MDS patients. Then there is a program in pancreatic cancer patients. The read out for those studies -- first of all the high-risk MDS read out, we will know top line data by fourth quarter of this year. Remember, this is an overall survival study. This is -- as far as the trial design, this is versus standard of care. Now, the longer patients will live, the better I assume it will be for the patient, but also for the outcome of the study here. But we expect fourth quarter 2013 to have the top line data for the high-risk. As far as the low-risk oral program, there will be response data by second quarter of this year. Then the timelines for the pancreatic study, we will have interim survivor data first quarter of 2014. As far as design is concerned -- so the sample for the high-risk is 270 patients, the enrollment is on target. I think we're close to 220 patients out of 270. The low-risk is 60 patients, we're more than half way in enrollment. The pancreatic is 150. We passed 110 patients enrollment. I hope that answers --
很好。所以,我們對這個也很興奮,你可以看到 2013 年有很多事情在進行。他們有三個計畫——或者說我們有三個計畫。一個是在高風險 MDS 病患的靜脈注射(IV)計畫。第二個是在低風險 MDS 病患的口服計畫。另外還有一個是在胰臟癌病患的計畫。這些研究的讀出——首先,高風險 MDS 的讀出,我們會在今年第四季知道主要(top line)數據。請記得,這是一項整體存活期(overall survival)研究。就試驗設計而言,這是與標準治療(standard of care)相比。當然,病人活得越久,我想對病人越好,也對研究結果越有利。但我們預期在 2013 年第四季取得高風險的主要數據。至於低風險口服計畫,今年第二季會有反應(response)數據。至於胰臟研究的時程,我們會在 2014 年第一季取得期中存活(interim survival)數據。就設計而言——高風險的樣本數是 270 位病人,收案進度符合目標。我想我們接近 270 位中的 220 位。低風險是 60 位病人,收案已超過一半。胰臟的是 150 位。我們已超過 110 位收案。希望這回答了——
- Chairman & CEO
- Chairman & CEO
So, Mike, you know this is European, right? So, Ludwig, just expand a bit.
所以,Mike,你知道這是歐洲的,對吧?所以,Ludwig,再多補充一點。
- Analyst
- Analyst
Yes, right.
是的,沒錯。
- Chairman & CEO
- Chairman & CEO
Could you comment on a couple of things. One, the magnitude of the opportunity, but before that maybe, why this is so complimentary with our channel presence, particularly in Europe.
你能評論幾件事嗎。第一,機會的規模;但在那之前,也許先談談為什麼這與我們的通路佈局、特別是在歐洲,會如此互補。
- President - Biosciences
- President - Biosciences
Yes, so as far as the opportunity financially, if we hit on all three, we believe this could become a $1 billion opportunity. When you look at our rights, we have EU territory. So, we have Europe -- so we have 33 countries. From a patient perspective, this could be big, because those patients, at least in the high-risk, don't have any treatment options available. So we would be able to make a significant impact in the lives of those patients. Then from a channel perspective, I do believe this is a very strong bolt-on and add-on to our Hemophilia franchise. MDS is right in the middle between hematology and oncology. At the end of the day, we're market leaders in the hemophilia. When you look at the channel in Europe, we're talking about centers of excellence. These are very specialized centers focusing on MDS, both low-risk and high-risk. We believe that we are in an excellent position to have a great partnership. When the data -- if and when the data is positive and we launch, that we can make a significant impact here.
是的,就財務機會而言,如果三個都成功,我們相信這可能成為一個 10 億美元的機會。就我們的權利來看,我們擁有歐盟區域的權利。也就是歐洲——我們涵蓋 33 個國家。從病患角度來看,這可能影響很大,因為這些病人,至少在高風險族群,沒有任何可用的治療選項。因此我們能對這些病人的生活帶來顯著影響。從通路角度來看,我確實認為這是對我們血友病事業部非常強的補強(bolt-on)與加值(add-on)。MDS 正好介於血液學與腫瘤學之間。歸根結底,我們在血友病領域是市場領導者。當你看歐洲的通路,我們談的是卓越中心(centers of excellence)。這些是非常專業的中心,專注於 MDS,包含低風險與高風險。我們相信我們處於極佳位置,能建立很好的合作夥伴關係。當數據——如果且當數據是正面的、並且我們上市時,我們可以在這裡帶來顯著影響。
- Analyst
- Analyst
Good. Just one follow-up, so the IV high-risk, once you have that read out and you submit that as orphan drug -- so if that goes well, you could be looking at EU approval late 2014? Is that fair, Ludwig?
很好。再追問一個,所以高風險的 IV,一旦你有了讀出並以孤兒藥提交——如果進展順利,你可能會在 2014 年底獲得歐盟核准?這樣說合理嗎,Ludwig?
- President - Biosciences
- President - Biosciences
Well, if US -- and US regulatory strategies and timelines are different -- we have Europe. For Europe, we will be looking at a 2015, because Europe doesn't have the same accelerated timelines as the FDA in the US.
嗯,如果美國——而且美國的監管策略與時程不同——我們還有歐洲。就歐洲而言,我們會看2015年,因為歐洲不像美國FDA那樣有相同的加速時程。
Operator
Operator
David Roman, Goldman Sachs.
David Roman,高盛。
- Analyst
- Analyst
I wanted to just come back to the Antibody Therapy business for a second, please. If I take your comments about successful demand creation through the SG&A line, conversion of Sub-Q -- but then square that against some of the capacity constraints that you've talked about, you're still getting a lot of growth out of that franchise in terms of dollars. Can you maybe help fit all the moving parts together? Maybe it's mix or price, just to help us understand how strong these numbers were in the context of a tough comp and the supply constraints.
我想請再回到抗體治療(Antibody Therapy)業務談一下。如果我把你們關於透過SG&A費用線成功創造需求、Sub-Q轉換的評論——但再對照你們提到的一些產能限制——你們在美元金額上仍然從該產品線取得了相當多的成長。你能否幫我們把所有變動因素串起來?也許是產品組合或價格,幫助我們理解在艱難的比較基期與供應限制下,這些數字到底有多強。
- CFO
- CFO
Yes, so we are operating under a supply constraint. None of that has changed. But as we've talked about, as we've had to look at global allocation of a constrained product here, US demand has been particularly strong. Prices tend to be higher in the US than most other markets. So as we've shifted product, we do get a mix benefit from that. That certainly has aided the top line growth profile there. Nothing new on the pricing front. We've talked about an expectation of modest price increase and that's what we expect to see here in 2013 as we saw in 2012. So I think, David, it's primarily the mix impact. As I mentioned earlier, we've largely done the shift that we're going to do. So as we move into 2013, there will be less of that from an impact. We will have a little bit of a year-over-year benefit in the first half of the year, but again, by the third or fourth quarter this year, we've largely made the shift we expected to make.
是的,所以我們是在供應受限的情況下營運。這一點沒有改變。但如同我們談過的,當我們必須在全球範圍內分配這個供應受限的產品時,美國的需求特別強勁。美國的價格通常高於大多數其他市場。因此,當我們調整產品供應配置時,確實會帶來組合(mix)上的好處。這當然也有助於該業務的營收成長表現。在定價方面沒有新消息。我們談過預期會有溫和的價格上調,而這正是我們在2013年預期會看到的情況,就像2012年一樣。所以我認為,David,主要是組合效應。如我先前提到的,我們基本上已完成我們要做的調整。因此進入2013年後,這方面的影響會變少。上半年會有一些年對年(YoY)的好處,但同樣地,到今年第三或第四季時,我們基本上已完成預期要做的調整。
- Chairman & CEO
- Chairman & CEO
The other thing I would just add to that, to what Bob said is, obviously, we continue the conversion to Sub-Q, which uses a higher volume. So that drives volume growth. We continue to operate primarily in the PI indication in under diagnose and an underdeveloped market even in the US. So we continue our focus on developing those markets. We continue to see expanded use in the whole neurology space, which as a general rule also uses volumes of drug at a higher level. So you have all kind of upward arrows, if you will, that are driving underlying demand. We just look forward to moving into a position where our capacity expands. The long-term outlook for this business is very robust.
另外我想補充Bob所說的,顯然我們仍在持續推動轉換到Sub-Q,而這會使用更高的用量。因此這會帶動用量成長。我們仍主要在PI適應症上運作,而即使在美國,這也是一個診斷不足且尚未充分開發的市場。因此我們持續專注於開發這些市場。我們也持續看到在整個神經科領域的使用擴大,而一般而言那也會以更高的水平使用藥量。所以可以說有各種向上的驅動因素在推升基礎需求。我們只是期待能進入產能擴張後的狀態。這項業務的長期展望非常強勁。
- Analyst
- Analyst
Okay.
好的。
- CFO
- CFO
David, one last thing to point out. That also then -- the stronger fourth quarter, plays in a little bit to some of the tightness and somewhat lower expectation for sales in Q1 of this year. As I mentioned, as we move throughout the course of this year, as we bring old LA back up -- so we'll have a better supply. But overall, we're still looking at approximately mid single-digit volume increase in 2013.
David,最後再指出一點。第四季較強的表現,也在一定程度上造成了今年第一季銷售較為吃緊、且預期略低的情況。如我所提到的,隨著今年進行,我們會讓舊的LA產能回升——因此供應會更好。但整體而言,我們仍預期2013年的用量約為中個位數百分比的成長。
- Analyst
- Analyst
Sure. That makes sense. Maybe just a follow-up on the P&L -- more on the cash flow side. You grew operating cash flow 10% this year, guiding to a similar type number in 2013. Obviously, you have a step up in CapEx associated with Georgia and the Gambro transaction, but is that type of cash generation just cash flow generation versus earnings growth sustainable over a long period of time? Then, how does that factor into your thinking on financial flexibility? The question came back up earlier about, can you do deals despite Gambro? But if this type of cash flow is sustainable and continues, I would assume that there is plenty of flexibility for more business development or further return of cash to shareholders.
當然。這很合理。也許就損益表(P&L)再追問一下——更偏向現金流的面向。你們今年營運現金流成長10%,並指引2013年也會是類似的數字。顯然你們的資本支出(CapEx)會因喬治亞(Georgia)以及Gambro交易而上升,但這種現金創造——也就是現金流成長相對於盈餘成長——長期來看是否可持續?另外,這如何影響你們對財務彈性的思考?先前又有人提到:即使做了Gambro,你們還能不能再做交易?但如果這種現金流是可持續且持續成長,我會假設你們在進一步的業務開發或把更多現金回饋股東方面,應該有很大的彈性。
- CFO
- CFO
David, I would agree with that. Let me kind of walk you through that. So the guidance we've given is about 7% increase in cash flow in 2013 versus 2012. It was a bit higher in 2012 versus 2011, because we had a pension contribution in 2011, didn't have one in 2012. But that 7% cash flow growth is very consistent with what we talked about in our long range plan outlook, for the business to grow cash flow to approximately $4.5 billion by the end of the long range plan. Yes, we do believe that is definitely achievable. Now, one thing to point out, one of the headwinds we've got here is pension expense, year-over-year another $0.10 headwind here as we go into 2013. More than 70% of that increase is related to non-cash amortization of actuarial losses on the balance sheet. So over the last three years, we've actually incurred $175 million cumulatively of additional pension expense or $0.25 a share.
David,我同意。我來大致帶你走一遍。我們給出的指引是:2013年的現金流相較2012年約成長7%。2012年相較2011年略高一些,因為2011年有一筆退休金提撥(pension contribution),2012年沒有。但這7%的現金流成長,與我們在長期計畫(long range plan)展望中所談到的非常一致:到長期計畫結束時,讓業務現金流成長到約45億美元。是的,我們確實認為這絕對可達成。另外要指出一點,我們面臨的一個逆風是退休金費用:年對年在進入2013年時又有每股0.10美元的逆風。其中超過70%的增加,與資產負債表上精算損失的非現金攤銷(non-cash amortization)有關。因此在過去三年,我們累計實際增加了1.75億美元的退休金費用,或每股0.25美元。
Again, about 75% of that is non-cash. So increasingly, you're going to see a divergence between earnings growth and cash flow growth, because of the impact of this non-cash amortization on the P&L that we don't see in the cash flow statement. So it does mask the strength of the underlying operating performance. We do feel good about our ability to continue to generate cash flow in that roughly 7% or in line with earnings as we go forward. That will, again, with the structure of the Gambro financing and use of offshore cash, leave us in a position of having strategic flexibility, continue to look at M&A and asset and capital allocation going forward here, including a strong and growing dividend at approximately a 40% pay out ratio.
同樣地,其中約75%是非現金。因此你會越來越看到盈餘成長與現金流成長之間出現分歧,因為這些非現金攤銷對損益表(P&L)有影響,但在現金流量表中看不到。所以它會掩蓋基礎營運表現的強勁程度。我們對於未來持續產生現金流的能力感到樂觀,大約能維持在7%左右,或與盈餘成長一致。再者,配合Gambro融資結構以及海外現金的運用,這會讓我們保持策略彈性,持續評估併購(M&A)、資產與資本配置,包括在約40%配息率(pay out ratio)下維持強勁且成長中的股利。
- Analyst
- Analyst
Then, maybe just one quick follow-up on that. If you look at the long range plan and then you obviously -- there have been many sort of headwinds every year on pension and things of that nature. How should we be thinking about those on a go forward basis? I don't mean for this to come off cynically, but do those go away at some point, whereby you do realize that long range plan growth rate? Or is cash flow a more appropriate way to look at things?
那麼再快速追問一下。如果你看長期計畫,然後你們顯然——每年在退休金等方面都有許多所謂的逆風。我們應該如何在未來看待這些因素?我不是想用很犬儒的角度來問,但這些因素是否會在某個時間點消失,讓你們能真正實現長期計畫的成長率?或者,用現金流來看會是更合適的方式?
- CFO
- CFO
Well, I would say, the answer relates to pension. We've done a lot in the last five or six years to try to mitigate risk. We've closed -- the US plant, a new entrance that's two-thirds of our overall footprint in terms of the liability. We've lowered our expected return on assets. We've changed the investment asset allocation mix to be 40% fixed income. We've bought treasuries of the hedge in the pension fund since 2008. But despite all that, we continue to see these headwinds. We did take an additional action here in the fourth quarter to offer lump sums to the terminated vested portion of our pension population, which is about 28% of the liability. That actually saved $0.05 per share. So in other words, our pension headwind would have been $0.15 per share in 2013 had we not taken that action. Despite all of that, again, we have this $0.10 headwind.
嗯,我會說,答案與退休金有關。在過去五、六年裡,我們做了很多事情來嘗試降低風險。我們已經關閉——美國的工廠,這是一個新的進入點,就負債而言約占我們整體規模的三分之二。我們也下調了資產的預期報酬率。我們已將投資資產配置組合調整為40%固定收益。自2008年以來,我們在退休金基金中買入國庫券作為避險。但儘管如此,我們仍持續看到這些逆風。我們確實在第四季採取了額外行動,向我們退休金人群中已終止但仍具既得權益的部分提供一次性給付,該部分約占負債的28%。那實際上為每股節省了0.05美元。換句話說,如果我們沒有採取該行動,2013年我們的退休金逆風本會是每股0.15美元。儘管如此,再次強調,我們仍有每股0.10美元的逆風。
However, given that most of this expense increase is this amortization and that this actuarial loss was heavily driven by the 2008 stock market performance. That usually amortizes over a five to seven year period. So going forward here, even if interest rates don't go up, we will see an improving pension situation and potentially a material tailwind here over the next several years. But at the moment, for 2013, given where we're at, it remains a headwind. So I think that one is one I feel increasingly comfortable is going to stop being a headwind and potentially become a tailwind. As it relates to austerity measures, which is really the other one -- that's a harder one to gauge. But as you know, in our LRP outlook, we did assume some ongoing austerity measures going forward.
不過,鑑於這次費用增加的大部分是攤銷,而且這項精算損失主要是由2008年股市表現所驅動。那通常會在五到七年的期間內攤銷。因此往前看,即使利率不上升,我們也會看到退休金狀況改善,並且在未來幾年可能出現顯著的順風。但就目前而言,對2013年來說,考量我們所處的位置,它仍然是逆風。所以我認為,這一項我越來越有信心會停止成為逆風,並可能轉為順風。至於緊縮措施——這其實是另一項——就比較難衡量。但如你所知,在我們的LRP展望中,我們確實假設未來仍會持續有一些緊縮措施。
- Chairman & CEO
- Chairman & CEO
Bob, would you comment on -- because I'm not sure everyone understands this. Why this whole pension thing is disproportionately greater for Baxter as a result of some legacy positions that were taken? Okay? Could you just expand on that for a minute?
Bob,你能否評論一下——因為我不確定每個人都理解這點。為什麼由於過去採取的一些歷史性安排,整個退休金議題對Baxter的影響會不成比例地更大?好嗎?你能否就此稍微延伸說明一下?
- CFO
- CFO
Sure. So as Bob mentioned, when the Allegiance spinoff was done in 1996 and the Edwards Lifescience spinoff was done in 1999, Management at the time decided to retain the assets and liabilities associated with those two spinoffs. As I mentioned, that ended up accounting for almost 30% of our overall pension liability today. That may have been a great decision back in the 1990s when stock markets were performing well and interest rates were high. But in the 2000s and where we're at today with the record low interest rates here, that has created an amplified effect on our P&L profile here more than you might otherwise expect. So again, we took some action here in the fourth quarter to try to offer lump sums to lower that exposure to that population and were successful and saved $0.05 a share. But that's one of the issues we've been dealing with here over the last several years.
當然。如Bob提到的,當1996年完成Allegiance分拆、以及1999年完成Edwards Lifescience分拆時,當時的管理層決定保留與這兩次分拆相關的資產與負債。如我所提到的,這最終約占我們目前整體退休金負債的近30%。在1990年代股市表現良好且利率較高時,那可能是個很好的決策。但在2000年代以及我們今天所處、利率創歷史低點的環境下,這使得我們的損益表(P&L)輪廓所受影響被放大,超出你原本可能預期的程度。因此,我們在第四季再次採取了一些行動,嘗試提供一次性給付以降低對該族群的曝險,且我們成功了,並為每股節省0.05美元。但這就是過去幾年我們一直在處理的問題之一。
- Analyst
- Analyst
That's an extremely helpful perspective. Thank you for going through that.
這個觀點非常有幫助。謝謝你詳細說明。
Operator
Operator
Bob Hopkins, Banc of America.
Bob Hopkins,美國銀行(Banc of America)。
- Analyst
- Analyst
So just to follow-up on the theme of pipeline updates. Two quick ones for me. One, on [HyQ] and one on Alzheimer's. First, on HyQ. I know you made some comments a couple weeks ago, but can you just update us on when you expect to meet with FDA and be able to communicate to us sort of a go forward details on the clinical trial requirements and new pathway for that?
那我就延續一下產品線更新的主題追問。我有兩個簡短問題。一個關於[HyQ],一個關於阿茲海默症。先談HyQ。我知道你們幾週前有一些評論,但你能否更新一下,預計何時會與FDA會面,並能向我們溝通後續的細節,例如臨床試驗要求以及新的申報路徑?
- Chairman & CEO
- Chairman & CEO
Okay. One of the reasons Ludwig is with us this morning. (laughter)
好的。這也是Ludwig今天早上和我們在一起的原因之一。(笑聲)
- President - Biosciences
- President - Biosciences
Oh, sure.
喔,當然。
- CFO
- CFO
It took us five questions to get there. But -- anyway, go ahead.
我們問了五個問題才到這裡。不過——總之,請繼續。
- President - Biosciences
- President - Biosciences
This is good, so thanks for the question. So first of all, from a European perspective, we continue the European regulatory process. We expect a decision -- we're talking about HyQ --
很好,謝謝你的問題。首先,從歐洲的角度來看,我們持續推進歐洲的法規程序。我們預期會有一個決定——我們在談HyQ——
- Chairman & CEO
- Chairman & CEO
HyQ and then Alzheimer's.
HyQ,然後是阿茲海默症。
- President - Biosciences
- President - Biosciences
First HyQ and then Alzheimer's. Thank you. So we're continuing the European regulatory process. We expect a decision first half of this year for Europe. Then with respect to the FDA for the US, we have confirmed a meeting with the FDA in the second quarter of this year. Where we will be discussing interim data from the pre-clinical studies that we are conducting. So we started those pre-clinical animal studies together with Halozyme -- in two animal models, the rabbits and the rats. We expect to complete these studies by year-end. So interim data will be discussed with the FDA second quarter of this year. Then the regulatory path forward, of course, will depend on the outcome of our meeting. That's the short version, on the HyQ. As far as --
先HyQ,然後阿茲海默症。謝謝。所以我們正在持續推進歐洲的法規程序。我們預期今年上半年會就歐洲做出決定。接著就美國方面的FDA而言,我們已確認將在今年第二季與FDA會面。屆時我們將討論我們正在進行的臨床前研究的期中數據。因此,我們與Halozyme一起啟動了這些臨床前動物研究——在兩種動物模型上,兔子與老鼠。我們預期在年底前完成這些研究。因此,今年第二季將與FDA討論期中數據。然後,後續的法規路徑當然將取決於我們會議的結果。以上是HyQ的簡短版本。至於——
- Analyst
- Analyst
Before you go to that, Bob, any follow-on, on the HyQ piece before Ludwig moves to Alzheimer's? No, I think, that's pretty straightforward.
在你轉到下一個之前,Bob,關於HyQ這部分,Ludwig轉到阿茲海默症之前,你還有要追問的嗎?沒有,我覺得這很清楚。
- Chairman & CEO
- Chairman & CEO
Okay, good. Please go ahead now.
好的,很好。請繼續。
- President - Biosciences
- President - Biosciences
Then Alzheimer's -- your question is overall status of where we are with the program?
那阿茲海默症——你的問題是我們在該計畫上的整體進度狀態嗎?
- Analyst
- Analyst
Yes, I was just wondering if the timelines that you laid out a couple weeks ago are still good? If there's any update there? You said previously that, you would soon unlock the data and begin the analysis. I'm just wondering, has the data been unlocked and has the analysis begun? Should we still anticipate a Q2 data release?
是的,我只是想確認你們幾週前提出的時間表是否仍然成立?是否有任何更新?你之前說你們很快會解鎖數據並開始分析。我想問的是,數據是否已解鎖、分析是否已開始?我們是否仍應預期第二季發布數據?
- President - Biosciences
- President - Biosciences
So yes. You should expect a data release second quarter of this year. As I mentioned, we have different assessments. We have clinical assessments. We have assessments at the brain level as well as CSF, as well as our plasma assessments. These assessments are done -- some of them are done by the investigator, these are the clinical assessments. But others are done by, I would say, a centralized lab, which takes a little bit longer. We are planning to close the database by the end of this quarter. That's when you're going to -- that's why you will see the data second quarter of this year.
是的。你應該預期今年第二季會發布數據。如我提到的,我們有不同的評估。我們有臨床評估。我們也有腦部層面的評估,以及CSF(腦脊髓液)的評估,還有血漿評估。這些評估——其中一些由研究者完成,也就是臨床評估。但其他的則由我所說的集中式實驗室完成,這會花更長時間。我們計畫在本季末關閉資料庫。那就是你會在今年第二季看到數據的原因。
- Analyst
- Analyst
Then what's a best case regulatory outlook for Alzheimer's? Just in terms of what the requirements will be for approval? Assuming you do have good data, obviously, you'd probably expect some incremental demand on IVIG, even though approval will take awhile. So I guess, just as last question, what's the best case regulatory outlook for the approval pathway? Then, how do you deal with the extra demand that you'll probably have for that product, knowing that it will be off-label if you do have positive data?
那麼,阿茲海默症在法規上的最佳情境展望是什麼?就核准所需的要求而言。假設你們確實有良好數據,顯然你們可能會預期IVIG會有一些額外需求,即使核准還需要一段時間。所以我想,最後一個問題:核准路徑在最佳情境下的法規展望是什麼?另外,如果你們確實有正面數據,考量在核准前會是適應症外使用(off-label),你們要如何應對該產品可能出現的額外需求?
- President - Biosciences
- President - Biosciences
Sure. Well, first of all, the robustness of the data will define our regulatory strategy. Plus the FDA and the European authorities will define our strategy moving forward. So it's difficult to speculate what the outcome will be of the study. So you know that we did a futility analysis. We know that on the basis of the futility analysis, the probability of success for achieving statistical significance in one or both of our primary endpoints is greater than 20%. So that's the only information that we know at this moment. So robustness -- what I mean by that is, you have a clinical assessment, these are our primary endpoints. You have a brain assessment. You have a plasma and you have a CSF. So that will define our discussion with the regulatory authorities and will define our regulatory pathway forward. So for me, at this point, it's very difficult to speculate how this is going to look like.
當然。嗯,首先,數據的穩健性將決定我們的監管策略。此外,FDA 與歐洲主管機關也將界定我們後續的策略。因此,很難推測這項研究的結果會是什麼。所以你知道我們做了無效性分析(futility analysis)。我們知道,根據無效性分析,在我們一個或兩個主要終點達到統計顯著性的成功機率大於 20%。所以這是我們目前唯一掌握的資訊。所謂穩健性——我的意思是,你有臨床評估,這些是我們的主要終點。你有腦部評估。你有血漿,還有 CSF(腦脊髓液)。因此,這將界定我們與監管機關的討論,並界定我們後續的監管路徑。所以對我而言,在這個時間點,很難推測這會呈現成什麼樣子。
It's too early. To bridge back to your question on data, so I mentioned you will have the data second quarter of this year. This will be the top line data that we will be releasing. We will -- we are planning to show all the details of all the different assessments at a major Alzheimer Congress in July. These are our timelines. Then, with respect to the NAMD, I think it's fair to say that we're not going to detail or promote the indication until we get the indication. The timing for that will be related to, of course, our regulatory strategy. Then Bob's already mentioned, the fact that we -- 2013 is a little bit of a transition period or transition year as far as IG volume is concerned, since we are upgrading LA1 -- old LA -- and so that will accelerate. We have new LA that's still accelerating. We have next year -- we have the Sanguin agreement that will come on board by the end of the year. Plus longer term, we have also the Covington opportunity plus we have re-etty. So 2013 being a transition year, picking up by the end of this year. Then new opportunities as of next year to further accelerate the volume.
現在還太早。回到你關於數據的問題,我剛才提到你會在今年第二季拿到數據。這將是我們要發布的頂線數據(top line data)。我們——我們計畫在 7 月的一個大型阿茲海默症大會上展示所有不同評估的全部細節。這些是我們的時間表。接著,關於 NAMD,我認為可以公平地說,在我們拿到適應症之前,我們不會去詳述或推廣該適應症。其時間點當然會與我們的監管策略相關。另外 Bob 已經提到,就 IG 產量而言,2013 年有點像是過渡期或過渡年,因為我們正在升級 LA1——舊的 LA——因此那將會加速。我們有新的 LA,仍在加速中。我們明年——我們與 Sanguin 的協議將在今年年底前納入。此外,長期來看,我們也有 Covington 的機會,另外還有 re-etty。所以 2013 年是過渡年,到今年年底會回升。然後從明年起有新的機會,進一步加速產量。
- Chairman & CEO
- Chairman & CEO
But the fact is, if ultimately the data is extremely compelling and A and B, there's no other emerging therapies, the reality is even with our expansion efforts which were just detailed by Ludwig, we would not be able to meet the demand for this. So it does require, I guess what I would describe as a different paradigm, a different approach. I think this whole notion of public-private partnerships, collaborations with governments ultimately is something that may have to be considered. Now obviously, it's too early to jump in the middle of that. Right now, we can control what we can control. There's a reason when we scope the Covington plant out, we did it with a broader vision beyond the 3 million litre capacity that we're initially putting in. So if the data emerges in a positive way, we can accelerate the ramp up longer term. So we continue to evaluate a variety of options in this regard, Bob. But suffice it to say, given the plasma-derived nature of the therapy and the number of patients conceivable that would need to be treated, it will require fundamentally different approaches -- a number of which we're obviously evaluating right now.
但事實是,如果最終數據非常具說服力,而且 A 與 B,沒有其他新興療法出現,現實是即便有我們剛才由 Ludwig 詳細說明的擴產努力,我們也無法滿足需求。因此,我想這需要——我會形容為——不同的典範、不同的方法。我認為所謂公私夥伴關係、與政府的合作,最終可能是必須考慮的事情。當然,現在就跳進那個議題的核心還太早。目前,我們能控制的就先控制好。我們在規劃 Covington 工廠時之所以這樣界定範圍,是因為我們的視野不只侷限於最初要建置的 300 萬公升產能。因此,如果數據以正面的方式呈現,長期來看我們可以加速爬坡擴產。所以我們持續評估在這方面的各種選項,Bob。但簡而言之,鑑於該療法屬於血漿衍生(plasma-derived)的性質,以及可想見需要治療的病患人數,這將需要根本不同的方法——其中有多種我們顯然正在評估中。
Operator
Operator
Rajeev Jashnani, UBS.
Rajeev Jashnani,瑞銀(UBS)。
- Analyst
- Analyst
I had a few questions. One on -- a couple maybe. The Hemophilia franchise, the guidance, I think was low to mid singles. I guess we don't have kind of the comparable number for 2012. I was wondering if you could help frame that in terms of what -- if you've rolled up FEIBA, plasma-derived, Recombinants -- what that growth rate would have been? It seems like -- or at least I would have thought, given the momentum in US Recombinants that perhaps that would have been a little bit stronger than that. Or perhaps there's just some conservatism baked-in there. Then maybe one for Ludwig. We kind of touched on this at the Analyst meeting. You discussed the ease-of-use for ADVATE, the time for infusion, or the simplicity of that. You had mentioned at that time the potential to further ease that process. I was wondering if, at this point, you'd be comfortable providing some more color around what some of those activities may be?
我有幾個問題。一個是——可能兩個。血友病產品線(franchise)的指引,我記得是低到中個位數成長。我想我們沒有 2012 年可對照的數字。我想請你幫忙框定一下:如果把 FEIBA、血漿衍生產品、重組產品(Recombinants)都合併計算,那個成長率會是多少?看起來——或者至少我原本以為,考量到美國重組產品的動能,那可能會比這更強一些。或者也許只是裡面納入了一些保守假設。接著可能有一題給 Ludwig。我們在分析師會議上稍微談到這點。你談到 ADVATE 的易用性、輸注時間,或其簡便性。你當時提到有可能進一步簡化那個流程。我想請問,在這個時間點,你是否願意就那些可能的活動提供更多說明?
- Chairman & CEO
- Chairman & CEO
Bob, you take the first part and then Ludwig --
Bob,你先回答第一部分,然後 Ludwig——
- CFO
- CFO
Yes, so Rajeev, a couple of things on hemophilia growth in 2013 versus 2012. In 2012, we saw a very robust growth for FEIBA particularly in the US -- off a less strong 2011. So we're growing off a much stronger base. While we're excited about the prophylaxis label potentially for FEIBA, that still is in submission phase here, so we can't actively promote that. So we have more modest FEIBA growth assumptions in the US in 2013 versus 2012. Then as it relates to recombinant Factor VIII, we've talked about in prior quarters, particularly in the first part of 2013, as there were shifts going on within the Specialty Pharma -- Pharmacy distribution channel within the US in terms of payer relationships and so on.
好的,Rajeev,關於 2013 年相較 2012 年的血友病成長,有幾點。2012 年,我們看到 FEIBA 的成長非常強勁,特別是在美國——是建立在 2011 年相對沒那麼強的基期之上。所以我們是從更強的基期往上成長。雖然我們對 FEIBA 可能取得預防性用藥標示(prophylaxis label)感到興奮,但目前仍在送件審查階段,因此我們不能積極推廣。因此,我們對 2013 年美國 FEIBA 的成長假設較 2012 年更為溫和。至於重組第八凝血因子(recombinant Factor VIII),我們在前幾季談過,特別是在 2013 年前半段,因為美國專科藥品——藥局(Specialty Pharma—Pharmacy)配銷通路在付款方關係等方面出現變動。
We did see some inventory build. I think, we gauged it at 2% to 3% of roughly 10% growth we were seeing in the first half of the year. So we need to work a little bit of that off as we go into 2013 as well. As Ludwig mentioned earlier and as we've mentioned at the Investor conference, we do expect some competition in recombinant Factor VIII in the US later this year. Could be of multiple players depending on timeline for approval of Novo and for Biogen Idec's longer acting. So we've baked that into our assumptions as well.
我們確實看到一些庫存建立。我想我們估計,在上半年約 10% 的成長中,其中有 2% 到 3% 來自庫存增加。因此,進入 2013 年時我們也需要逐步消化其中一部分。如同 Ludwig 先前提到、以及我們在投資人會議上提到的,我們確實預期今年稍晚在美國的重組第八凝血因子市場會出現一些競爭。視 Novo 的核准時程以及 Biogen Idec 的長效型產品核准時程而定,可能會有多家競爭者。因此我們也已把這些因素納入假設。
- President - Biosciences
- President - Biosciences
So, Rajeev, as far as the infusion experience is concerned, the total infusion experience takes about five minutes. The infusion itself takes 30 seconds to one minute, of course, it depends on the experience. It depends on the volume and so on. But you also know that, we changed the deliverance, the volume of our vials awhile ago. We are now the lowest volume of 2ml, so we're talking about very limited volumes, which of course shortens the infusion time. We also have plans, as I mentioned at the investors conference in October, we also have plans to upgrade our Baxject II to our Baxject III device. We have not disclosed how it looks like, but again, it will be an upgrade. It will be a great experience for the patient. We're planning to launch the device before the end of this year.
所以,Rajeev,就輸注體驗而言,整體輸注流程大約需要五分鐘。實際輸注本身需要 30 秒到 1 分鐘,當然,這取決於熟練程度。也取決於容量等等。但你也知道,我們一段時間前就改變了我們小瓶的供應方式與容量。我們現在的容量最低為 2ml,所以我們談的是非常有限的容量,這當然縮短了輸注時間。此外,正如我在 10 月的投資人會議上提到的,我們也計畫把 Baxject II 升級為 Baxject III 裝置。我們尚未揭露它的外觀,但同樣地,這將是一項升級。對病患而言會是很棒的體驗。我們計畫在今年年底前推出該裝置。
- Analyst
- Analyst
Thanks. If I could sneak in one more, maybe for Bob. Could you just talk about -- you talked about the clinical aspects with Alzheimer's and some of the regulatory aspects. Could you touch on the commercial end for Alzheimer's, IVIG? What level of bandwidth that's receiving internally or is that something you wait until you see the data and then that -- step up the activity from that point forward? Thanks.
謝謝。如果我可以再插問一個,可能是給 Bob。你能否談談——你談到了阿茲海默症的臨床面以及一些法規層面。你能否觸及阿茲海默症在商業端、IVIG 的部分?內部目前投入了多大程度的資源在這上面?還是說要等看到數據之後,才會——從那個時間點起加大相關活動?謝謝。
- Chairman & CEO
- Chairman & CEO
Yes, there's virtually no activity in that aspect of it, Rajeev, to be very candid.
是的,Rajeev,坦白說,在那個面向幾乎沒有任何活動。
Operator
Operator
Matt Miksic, Piper Jaffrey.
Matt Miksic,Piper Jaffrey。
- Analyst
- Analyst
Just a couple of follow-ups. I think you talked a little bit about the conversion, it sounded like maybe you added 1 point or so, maybe more.
再追問幾點。我想你稍微談到了一些轉換,聽起來你們可能增加了大約 1 個百分點左右,或許更多。
- Chairman & CEO
- Chairman & CEO
Conversion of?
什麼的轉換?
- Analyst
- Analyst
Conversion of on-demand to prophy based on the label.
依照標籤,從按需用藥轉換到預防性用藥(prophy)的轉換。
- Chairman & CEO
- Chairman & CEO
Yes. Okay.
是的。好的。
- Analyst
- Analyst
Yes. I wanted to get a sense of -- you dialed-in a certain amount of competitive pressure, you talked about in the US. I'd love to understand maybe what kind of share you feel like you're gaining laterally, not just in terms of converting patients? What kind of uptake you've seen from a couple of the convenience aspects that you've rolled out in Hemophilia, namely twice-week dosing and the larger vial -- the prophy vial. Then I have one follow-up.
是的。我想了解一下——你們已納入一定程度的競爭壓力,你談到了在美國的情況。我很想了解你們覺得自己在橫向上獲得了什麼樣的市占提升,不只是把病患轉換過來而已?另外,你們在血友病領域推出的一些便利性措施所帶來的採用情況如何,尤其是每週兩次給藥以及較大瓶裝——也就是預防用瓶裝。然後我還有一個追問。
- Chairman & CEO
- Chairman & CEO
Yes, I don't think that we're in a position to quantify at this stage, the share impact. I would just -- suffice it to say, Matt, that as Ludwig mentioned earlier, we're encouraged with the uptake and the response to the prophy. We're looking forward to some of the other -- such as the Baxject III launch later in the year. I would just say, our momentum right now particularly in the US in Hemophilia is the strongest its been in at least a couple years, if not longer. Obviously, we're going to do everything to not only maintain that and enhance that, but to quantify that in terms of shares is probably a little bit premature, okay?
是的,我不認為我們在這個階段能量化市占影響。我只想——Matt,簡單說,正如 Ludwig 先前提到的,我們對預防用藥的採用與回饋感到鼓舞。我們也期待今年稍晚其他項目——例如 Baxject III 的上市。我只能說,我們目前在美國血友病業務的動能,是至少兩年來最強的,甚至可能更久。顯然,我們會盡一切努力不僅維持並強化這股動能,但要以市占來量化,可能還稍嫌過早,好嗎?
- Analyst
- Analyst
So just to be clear, I guess I'm trying to understand -- the one benefit is getting on-demand patients to go to prophy with the label. The other is getting prophy patients to go to twice a week. Any sense of the uptake there?
所以為了確認清楚,我想了解——其中一個好處是透過標籤讓按需用藥的病患轉到預防用藥。另一個是讓原本做預防用藥的病患改成每週兩次。對於那邊的採用情況有什麼概念嗎?
- Chairman & CEO
- Chairman & CEO
Ludwig, why don't you comment on each of those?
Ludwig,你要不要針對這兩點各自評論一下?
- President - Biosciences
- President - Biosciences
It's difficult to give you numbers here. But the way that we look at this for us -- this is also how we rolled out the launch of this new indication, is that for us, the efficacy and the safety message is first, before the convenience. When you talk to patients, when you talk to physicians, it's about controlling their bleeds. Our vision for the organization is to strive towards a bleed-free world. That's what counts, much more than moving patients from every two days to every three days. So our launch was staggered. We started with the efficacy message, beginning of 2012 and only after six or nine months into the year, we started working on the moving towards every three day dosing regimen. Because clearly, we heard our patients and our physicians, that it's the efficacy controlling the bleeds that counts.
這裡很難給你數字。但我們看待這件事的方式——這也是我們推出這個新適應症的方式——對我們而言,效力與安全性的訊息優先於便利性。當你和病患談、和醫師談,重點在於控制出血。我們對組織的願景是朝向一個無出血的世界努力。這才是最重要的,遠比把病患從每兩天一次改成每三天一次更重要。所以我們的上市推廣是分階段進行的。我們在 2012 年初先從效力訊息開始,直到當年過了六到九個月之後,才開始推動往每三天一次的給藥方案。因為很明顯地,我們從病患與醫師那裡聽到的是:最重要的是效力、是控制出血。
- Corporate VP - IR
- Corporate VP - IR
Yes. Matt I would just add, we really started to promote that with the 4000 IU approval that we received late in the second quarter or third quarter of last year. In the fourth quarter, frankly, we saw good uptake of the 4000 IU, which is probably a good indication of conversion that we're seeing to two day dosing with our units being about 10% of our total units in the fourth quarter of the 4000 IU. So we are seeing uptake there.
是的。Matt,我只補充一點:我們其實是在去年第二季末或第三季末取得 4000 IU 核准後,才真正開始推廣這件事。坦白說,在第四季我們看到 4000 IU 的採用良好,這可能是我們看到轉換到兩天一次給藥的良好指標;以單位數來看,第四季 4000 IU 約占我們總單位數的 10%。所以我們確實看到那邊的採用。
- Analyst
- Analyst
Great. One follow-up, just on plasma and FEIBA. Just to be clear, I wasn't sure if you had mentioned this, but have you started firing up those plants again? Or are you just on track to do it here early in the year? Then on FEIBA, sort of a background question. I'm not sure if -- is FEIBA caught up in any of the supply issues related to your fractionation facility maintenance? Or is that just -- do you have plenty of supply there?
很好。再追問一點,關於血漿和 FEIBA。為了確認清楚,我不確定你是否提過:你們是否已經開始讓那些工廠重新啟動?還是說你們只是按計畫在今年年初啟動?另外關於 FEIBA,算是一個背景問題。我不確定——FEIBA 是否受到你們分餾設施維護相關供應問題的影響?還是說——你們那邊供應很充足?
- Chairman & CEO
- Chairman & CEO
We have sufficient supply in FEIBA. Bob, why don't you comment on the plant situation and the timing.
我們的 FEIBA 供應充足。Bob,你要不要談談工廠狀況與時程?
- CFO
- CFO
Yes. So we took the older LA facility down in the September timeframe. We completed all of the work that we expected to do. So we're in the process of preparing to start the plant up for production in the back half of February. So everything is on schedule. We'll have product available to the market in the third quarter, is the timeframe. No changes there.
好的。我們在 9 月左右讓較舊的洛杉磯(LA)設施停工。我們完成了所有預期要做的工作。因此,我們正準備在 2 月下旬讓工廠重新啟動生產。一切都按計畫進行。我們預計在第三季向市場供貨,時程就是如此。沒有任何變更。
Operator
Operator
Ladies and gentlemen, this concludes today's conference call with Baxter International. Thank you for participating.
各位女士、先生,今天 Baxter International 的電話會議到此結束。感謝各位參與。